Search

Your search keyword '"Corbelli J"' showing total 115 results
Start Over Author "Corbelli J"
115 results on '"Corbelli J"'

1. Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study

Author

Casadei-Gardini A, Scarpi E, Ulivi P, Palladino MA, Accettura C, Bernardini I, Spallanzani A, Gelsomino F, Corbelli J, Marisi G, Ruscelli S, Valgiusti M, Frassineti GL, and Passardi A

Subjects
Metastatic colorectal cancer, bevacizumab, first line, prognosis, Lactate dehydrogenase, Neutrophil-to-lymphocyte ratio., Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Andrea Casadei-Gardini,1 Emanuela Scarpi,2 Paola Ulivi,3 Maria Angela Palladino,4 Caterina Accettura,5 Ilaria Bernardini,6 Andrea Spallanzani,7 Fabio Gelsomino,7 Jody Corbelli,8 Giorgia Marisi,8 Silvia Ruscelli,1 Martina Valgiusti,1 Giovanni Luca Frassineti,1 Alessandro Passardi11Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; 2Unit of Biostatistics and Clinical Trials, IRST IRCCS, Meldola, Italy; 3Biosciences Laboratory, IRST IRCCS, Meldola, Italy; 4Medical Oncology Department, Piacenza Hospital, Piacenza, Italy; 5Medical Oncology Unit, Vito Fazzi Hospital, Lecce, Italy; 6Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy; 7Department of Oncology and Hematology, Division of Oncology, University Hospital Modena, Modena, Italy; 8Oncolgy Unit, Degli Infermi Hospital, Faenza, ItalyAim: The aim of this study was to investigate the role of a new inflammatory index (Colon Inflammatory Index [CII]) as a predictor of prognosis and treatment efficacy in patients with metastatic colorectal cancer (mCRC) enrolled in the prospective multicenter randomized ITACa (Italian Trial in Advanced Colorectal Cancer) trial to receive first-line chemotherapy (CT)+ bevacizumab or CT alone.Patients and methods: Between November 14, 2007 and March 6, 2012, 276 patients diagnosed with CRC were available for baseline neutrophil-to-lymphocyte ratio (NLR) and lactate dehydrogenase (LDH). We divided the population into three groups on basis of the CII index.Results: At baseline in all populations, median PFS and OS was predictive of clinical outcome (p

Published
2019

2. Prognostic Role of a New Inflammatory Index with Neutrophil-to-Lymphocyte Ratio and Lactate Dehydrogenase (CII: Colon Inflammatory Index) in Patients with Metastatic Colorectal Cancer: Results from the Randomized Italian Trial in Advanced Colorectal Cancer (ITACa) Study [Corrigendum]

Author

Casadei-Gardini A, Scarpi E, Ulivi P, Palladino MA, Accettura C, Bernardini I, Spallanzani A, Gelsomino F, Corbelli J, Marisi G, Ruscelli S, Valgiusti M, Frassineti GL, and Passardi A

Subjects
metastatic colorectal cancer, bevacizumab, first line, prognosis, lactate dehydrogenase, neutrophil-to-lymphocyte ratio., Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Casadei-Gardini A, Scarpi E ,Ulivi P, et al. CancerManag Res. 2019;11:4357– 4369.The authors have advised that the affiliations are not correct in the published paper (page 4357). They have provided revised author and affiliations lists as follows, and confirm that the modifications do not alter their conflicts of interest status in regard to this work.The authors confirm that the revised affiliation list reflects each of the author’s affiliations at the time of the study.Read the original article

Published
2020

3. Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial

Author

Grassi, E., Zingaretti, C., Petracci, E., Corbelli, J., Papiani, G., Banchelli, I., Valli, I., Frassineti, G.L., Passardi, A., Di Bartolomeo, M., Pietrantonio, F., Gelsomino, F., Carandina, I., Banzi, M., Martella, L., Bonetti, A.V., Boccaccino, A., Molinari, C., Marisi, G., Ugolini, G., Nanni, O., and Tamberi, S.

Published
2023
Full Text
View/download PDF

4. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial

Author

Tardif, Jean-Claude, Ballantyne, Christie M, Barter, Philip, Dasseux, Jean-Louis, Fayad, Zahi A, Guertin, Marie-Claude, Kastelein, John JP, Keyserling, Constance, Klepp, Heather, Koenig, Wolfgang, L'Allier, Philippe L, Lespérance, Jacques, Lüscher, Thomas F, Paolini, John F, Tawakol, Ahmed, Waters, David D, Pfeffer, M, Brown, V, Rouleau, J, Watkins, P, Wei, LJ, Gosselin, G, Chayer, C, Lanthier, S, Pelletier, GB, Racine, N, Agarwal, H, Brilakis, E, Cannon, L, Carrié, D, Corbelli, J, Coste, P, de Winter, R, Diaz, A, Eisenberg, S, Ennis, B, Fajadet, J, Fam, N, Fortuin, D, Gessler, C, Grines, C, Guerra, D, Gum, H, Haldis, T, Heestermans, T, Herrman, JP, Huynh, T, Kedhi, E, Koren, M, Kouz, S, Krolick, M, Kumkumian, G, Lavi, S, Li, RJ, Masud, ARZ, McAlhany, C, McGrew, FA, O'Shaughnessy, C, Ophuis, AJM Oude, Parr, K, Penny, W, Pesant, Y, Post, H, Robinson, S, Rodes-Cabau, J, Roy, A, Schulman, S, Spence, F, Stouffer, G, Stys, T, Sussex, B, Tahirkheli, N, Tardif, J-C, Grégoire, J, Berg, J ten, van Boven, AJ, von Birgelen, C, and Weinstein, D

Subjects
Aging, Clinical Trials and Supportive Activities, Atherosclerosis, Clinical Research, Cardiovascular, Heart Disease - Coronary Heart Disease, Heart Disease, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Acute Coronary Syndrome, Adult, Aged, Aged, 80 and over, Apolipoprotein A-I, Cardiovascular Agents, Coronary Angiography, Coronary Artery Disease, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Phospholipids, Prospective Studies, Recombinant Proteins, Treatment Outcome, Ultrasonography, Coronary disease, High-density lipoproteins, Clinical trial, Can HDL Infusions Significantly QUicken Atherosclerosis REgression (CHI-SQUARE) Investigators, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular System & Hematology
Abstract

AimHigh-density lipoproteins (HDLs) have several potentially protective vascular effects. Most clinical studies of therapies targeting HDL have failed to show benefits vs. placebo.ObjectiveTo investigate the effects of an HDL-mimetic agent on atherosclerosis by intravascular ultrasonography (IVUS) and quantitative coronary angiography (QCA).Design and settingA prospective, double-blinded, randomized trial was conducted at 51 centres in the USA, the Netherlands, Canada, and France. Intravascular ultrasonography and QCA were performed to assess coronary atherosclerosis at baseline and 3 (2-5) weeks after the last study infusion.PatientsFive hundred and seven patients were randomized; 417 and 461 had paired IVUS and QCA measurements, respectively.InterventionPatients were randomized to receive 6 weekly infusions of placebo, 3 mg/kg, 6 mg/kg, or 12 mg/kg CER-001.Main outcome measuresThe primary efficacy parameter was the nominal change in the total atheroma volume. Nominal changes in per cent atheroma volume on IVUS and coronary scores on QCA were also pre-specified endpoints.ResultsThe nominal change in the total atheroma volume (adjusted means) was -2.71, -3.13, -1.50, and -3.05 mm(3) with placebo, CER-001 3 mg/kg, 6 mg/kg, and 12 mg/kg, respectively (primary analysis of 12 mg/kg vs. placebo: P = 0.81). There was also no difference among groups for the nominal change in per cent atheroma volume (0.02, -0.02, 0.01, and 0.19%; nominal P = 0.53 for 12 mg/kg vs. placebo). Change in the coronary artery score was -0.022, -0.036, -0.022, and -0.015 mm (nominal P = 0.25, 0.99, 0.55), and change in the cumulative coronary stenosis score was -0.51, 2.65, 0.71, and -0.77% (compared with placebo, nominal P = 0.85 for 12 mg/kg and nominal P = 0.01 for 3 mg/kg). The number of patients with major cardiovascular events was 10 (8.3%), 16 (13.3%), 17 (13.7%), and 12 (9.8%) in the four groups.ConclusionCER-001 infusions did not reduce coronary atherosclerosis on IVUS and QCA when compared with placebo. Whether CER-001 administered in other regimens or to other populations could favourably affect atherosclerosis must await further study. Name of the trial registry: Clinicaltrials.gov; Registry's URL: http://clinicaltrials.gov/ct2/show/NCT01201837?term=cer-001&rank=2;Trial registration numberNCT01201837.

Published
2014

5. Emergency contraception: a review.

Author

Corbelli, J and Bimla Schwarz, E

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Contraception/Reproduction, Prevention, Clinical Research, Reproductive health and childbirth, Good Health and Well Being, Contraception, Postcoital, Contraceptives, Postcoital, Female, Humans, Intrauterine Devices, Copper, Levonorgestrel, Male, Nonprescription Drugs, Norpregnadienes, Patient Education as Topic, Pregnancy, Clinical Sciences, Obstetrics & Reproductive Medicine, Reproductive medicine
Abstract

Emergency contraceptives (EC) are forms of contraception that women can use after intercourse to prevent pregnancy. EC use is safe for women of all ages, and there are no medical contraindications to its use. There are two types of emergency contraceptive pills currently available: ulipristal acetate (UPA) and levonorgestrel. UPA is the most effective oral option for EC. In the United States, levonorgestrel containing ECPs are available without prescription to women and men without age restrictions. However, the more effective UPA pills require a prescription. ECPs do not cause abortion or harm an established pregnancy. Placement of a copper intrauterine device (IUD) is more effective EC than either UPA or levonorgestrel, and requires a timely visit with a trained clinician. EC pills are less effective for women who are overweight or obese, therefore such women should be offered a copper IUD or ulipristal rather than levonorgestrel pills. Any woman requesting EC after unprotected intercourse should be offered treatment within 120 hours of intercourse, as should all women who are victims of sexual assault. Women requesting EC should be offered information and services for ongoing contraception. Although levonorgestrel EC is now available over-the-counter, ongoing need exists to educate women about emergency contraception to encourage prompt use of EC when it is needed.

Published
2014

6. A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study

Author

Barbera, M.A., primary, Corbelli, J., additional, Papiani, G., additional, Grassi, E., additional, Ugolini, G., additional, Montroni, I., additional, Bartolomeo, M Di, additional, Cascinu, S., additional, Marzola, M., additional, Bonetti, A., additional, Frassineti, G.L., additional, Nanni, O., additional, Zattoni, D., additional, Ghignone, F., additional, Taffurelli, G., additional, Pinto, C., additional, Moretti, C Carli, additional, Rossi, G., additional, Palazzi, S., additional, and Tamberi, S., additional

Published
2019
Full Text
View/download PDF

7. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial†

Author

Tardif, Jean-Claude, Ballantyne, Christie M., Barter, Philip, Dasseux, Jean-Louis, Fayad, Zahi A., Guertin, Marie-Claude, Kastelein, John J. P., Keyserling, Constance, Klepp, Heather, Koenig, Wolfgang, L'Allier, Philippe L., Lespérance, Jacques, Lüscher, Thomas F., Paolini, John F., Tawakol, Ahmed, Waters, David D., Pfeffer, M., Brown, V., Rouleau, J., Watkins, P., Wei, L.J., Gosselin, G., Chayer, C., Lanthier, S., Pelletier, G.B., Racine, N., Agarwal, H., Brilakis, E., Cannon, L., Carrié, D., Corbelli, J., Coste, P., de Winter, R., Diaz, A., Eisenberg, S., Ennis, B., Fajadet, J., Fam, N., Fortuin, D., Gessler, C., Grines, C., Guerra, D., Gum, H., Haldis, T., Heestermans, T., Herrman, J.P., Huynh, T., Kedhi, E., Koren, M., Kouz, S., Krolick, M., Kumkumian, G., Lavi, S., Li, R.J., Masud, ARZ, McAlhany, C., McGrew, F.A., O'Shaughnessy, C., Oude Ophuis, A.J.M., Parr, K., Penny, W., Pesant, Y., Post, H., Robinson, S., Rodes-Cabau, J., Roy, A., Schulman, S., Spence, F., Stouffer, G., Stys, T., Sussex, B., Tahirkheli, N., Tardif, J-C, Grégoire, J., ten Berg, J., van Boven, A.J., von Birgelen, C., and Weinstein, D.

Abstract

Aim High-density lipoproteins (HDLs) have several potentially protective vascular effects. Most clinical studies of therapies targeting HDL have failed to show benefits vs. placebo. Objective To investigate the effects of an HDL-mimetic agent on atherosclerosis by intravascular ultrasonography (IVUS) and quantitative coronary angiography (QCA). Design and setting A prospective, double-blinded, randomized trial was conducted at 51 centres in the USA, the Netherlands, Canada, and France. Intravascular ultrasonography and QCA were performed to assess coronary atherosclerosis at baseline and 3 (2-5) weeks after the last study infusion. Patients Five hundred and seven patients were randomized; 417 and 461 had paired IVUS and QCA measurements, respectively. Intervention Patients were randomized to receive 6 weekly infusions of placebo, 3 mg/kg, 6 mg/kg, or 12 mg/kg CER-001. Main outcome measures The primary efficacy parameter was the nominal change in the total atheroma volume. Nominal changes in per cent atheroma volume on IVUS and coronary scores on QCA were also pre-specified endpoints. Results The nominal change in the total atheroma volume (adjusted means) was −2.71, −3.13, −1.50, and −3.05 mm3 with placebo, CER-001 3 mg/kg, 6 mg/kg, and 12 mg/kg, respectively (primary analysis of 12 mg/kg vs. placebo: P = 0.81). There was also no difference among groups for the nominal change in per cent atheroma volume (0.02, −0.02, 0.01, and 0.19%; nominal P = 0.53 for 12 mg/kg vs. placebo). Change in the coronary artery score was −0.022, −0.036, −0.022, and −0.015 mm (nominal P = 0.25, 0.99, 0.55), and change in the cumulative coronary stenosis score was −0.51, 2.65, 0.71, and −0.77% (compared with placebo, nominal P = 0.85 for 12 mg/kg and nominal P = 0.01 for 3 mg/kg). The number of patients with major cardiovascular events was 10 (8.3%), 16 (13.3%), 17 (13.7%), and 12 (9.8%) in the four groups. Conclusion CER-001 infusions did not reduce coronary atherosclerosis on IVUS and QCA when compared with placebo. Whether CER-001 administered in other regimens or to other populations could favourably affect atherosclerosis must await further study. Name of the trial registry: Clinicaltrials.gov; Registry's URL: http://clinicaltrials.gov/ct2/show/NCT01201837?term=cer-001&rank=2; Trial registration number: NCT01201837

Published
2017

8. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF

Author

Pokorney, Sean D, Piccini, Jonathan P., Stevens, Susanna R., Patel, Manesh R., Pieper, Karen S., Halperin, Jonathan L., Breithardt, Günter, Singer, Daniel E., Hankey, Graeme J., Hacke, Werner, Becker, Richard C., Berkowitz, Scott D., Nessel, Christopher C., Mahaffey, Kenneth W., Fox, Keith A. A., Califf, Robert M., Anderson, J., Bedwell, N., Bilsker, M., Bruce, G., Agah, R., Desantis, M., Eisenberg, S., Flores, A., Herzog, W., Klein, S., Snyder, H., Krueger, S., Almaguer, E., Lavie, E., Lee, C., Mallis, G., Modi, M., Woodworth, G., Niazi, I., Peart, B., Sundaram, S., Snoddy, B., Sotolongo, R., Moloney, J., Vijayaraghavan, K., Whittier, F., Yellen, L., Banerjee, S., Lustgarten, D., Suresh, D., Gelernt, M., Levinson, L., Ghanekar, R., Kneller, G., Hall, C., Fadl, Y., Pirwitz, M., French, W., Mayer, N., Pugeda, J., Steel, K., Mody, F., Malik, A., Chandna, H., Go, A., Emlein, G., Bowden, W., Moscoso, R., Hodson, R., Berk, M., Pan, D., Pappas, J., Orchard, R., Lynchard, G., Vijay, N., Khan, W., El Khadra, M., Antonishen, M., Cucher, F., Staab, M., Zebrack, J., Borromeo, S., Heilman, J., Chaturvedi, S., Makam, S., Turk, S., Hyers, T., Williams, G., Labroo, A., Gill, S., Myears, D., Weinstein, J., Shanes, J., Chandrashekhar, Y., Shah, S., Reiter, W., Logemann, T., Almquist, A., Bhagwat, R., Tak, T., Shen Ling, J., Patel, P., Artis, A., Arouni, A., Lauer, M., Kinney, K., Elsen, J., Roan, P., Villafria, R., Sumpter, M., Ip, J., Welka, S., Schifferdecker, B., Sandoval, R., Speirs, S., Jones, A., Haldis, T., Kazmierski, J., Sutherland, J., Dietrich, D., Telfer, E., Berry, J., Mcelveen, A., Russell, J., Sackett, M., Antonios, N., Smith, D., Vora, K., Kirby, A., Lui, H., Mego, D., Ziada, K., Navas, J., Taussig, A., Koren, M., Vogel, C., Saba, F., Parrott, C., Schneider, R., Shirwany, A., Rubin, M., Treasure, C., Bertolet, B., Chang, M., Langberg, J., Becker, R., Cohen, Y., Mcgrew, F., White, J., Arzola, F., Zelenka, J., Tannenbaum, A., Fernandes, V., Jamnadas, P., Agamasu, J., Collins, B., Jauch, W., Sasseen, B., Hotchkiss, D., Abadier, R., Osunkoya, A., Schlau, A., Chappel, C., Foster, M., Braun, E., Mostel, E., Capo, J., Ashchi, M., Howard, V., Albirini, A., Burger, A., Rolston, D., Staniloae, C., Bacon, J., Wiseman, A., Mcgarvey, J., Sonel, A., Hamroff, G., Chang, D., Daboul, N., Broderick, G., Meholick, A., Corbelli, J., Silverman, R., Raffetto, J., Fishberg, R., Georgeson, S., Held, J., Seidner, M., Saint Jacques, H., Heitner, J., Kutalek, S., Friedlander, I., Hutchinson, B., Walia, J., Kondo, N., Smiley, N., Blitz, L., Dale, H., Sulman, S., Szulawski, I., Modares, F., Martin, R., Nahhas, A., Renzi, M., Akyea Djamson, A., Alfieri, A., Sandhu, J., Voyce, S., Amaram, S., Meyerrose, G., Shoukfeh, M., Lee, F., Villegas, B., Idowu, O., Khera, A., Sam, C., Vo, A., Lieber, I., Smith, T., Awan, N., Tsai, C., Ganim, R., Alzaghrini, G., Pitt, W., Shepherd, A., Tang, S., Stoltz, S., Nelson, W., Cox, S., Meymandi, S., Melucci, M., Thomas, G., Gogia, H., Machell, C., Chandrasekaran, S., Brown, C., Jetty, P., Miller, G., Dykstra, G., Jaffrani, N., Zakhary, B., Caruso, A., Zolty, R., Fox, D., Jacobs, G., Lebenthal, M., Mukherjee, S., Zimetbaum, P., Kingsley, J., Jones, R., Robinson, V., Kenton, D., Usedom, J., Williams, S., Snipes, C., Wilson, V., Hasty, R., Shoemaker, J., Donahue, M., Al Saghir, Y., Thomsen, E., Yarows, S., Chastain, S., Mclaughlin, P., Wakham, M., Shrestha, D., Simmons, J., Fisher, D., Seymour, Z., Frandsen, B., First, B., Sharpe, C., Popeil, L., Guthrie, R., Hunter, J., Alvarado, O., Sandberg, J., Gutman, N., Belber, A., Arkhipov, M., Ballyzek, M., Baranov, A., Barbarash, O., Barbarich, V., Belenky, D., Berkovich, O., Bokarev, I., Boyarkin, M., Vaniev, S., Volkova, E., Gratsiansky, N., Demin, A., Zadionchenko, V., Zateyshchikov, D., Zrazhevsky, K., Mazaev, V., Martynov, A., Mikhailov, S., Mkrtchian, V., Novozhenov, V., Raskina, T., Rebrov, A., Sanina, N., Simanekov, V., Sitnikova, M., Smolenskaya, O., Stryuk, R., Storozhakov, G., Tankhilevich, B., Tereschenko, S., Khokhlov, A., Khrustalev, O., Chernov, S., Shvarts, Y., Shubik, Y., Shulman, V., Yakushin, S., Bugrova, O., Ivleva, A., Libis, R., Khozyainova, N., Maslov, S., Baranova, E., Sherenkov, A., Libov, I., Lusov, V., Chumakova, G., Kuznetsov, V., Ryamzina, I., Reshetko, O., Boldueva, S., Alekseeva, N., Novikova, T., Dvornikov, V., Idrisova, E., Shostak, N., Yarokhno, N., Tebloev, K., Treshkur, T., Mazurov, V., Loktin, E., Sedavnyh, I., Alexeeva, O., Yakhontova, P., Repin, A., Izmozherova, N., Kostenko, V., Fokin, A., Ketova, G., Kouz, S., Leader, R., Ayala Paredes, F., Luton, R., Ma, P., Pandey, S., Pesant, Y., Senior, R., Vertes, G., Bell, A., Crowley, D., Vizel, S., Lasko, B., Landry, D., Berger, L., Heath, J., Bessoudo, R., Ling, M., Tellier, G., Berlingieri, J., Kafka, H., Hill, L., Mazza, G., O'Mahony, W., Chilvers, M., O'Mahony, M., Newman, D., Silagy, S., Heffernan, M., Bennett, M., Bhesania, T., Rockman, G., Ng, K., Kalra, B., Meneses, G., Liang, W., Cheung, M., Kozak, J., Pugen, G., Vavougios, J., Kates, M., Nunes Vaz, C., Jaffer, S., Orfi, J., Faiers, A., Chung, C., Felsen, S., Bergman, S., Bernstein, I., Brownscombe, L., Stockdill, J., Silver, E., Ezekiel, D., Jagan, N., Khurana, M., Reisler, H., Goldman, H., Maung, T., Wong, F., Gillis, G., Vexler, R., Goldberg, B., Luterman, M., Gould, D., Coutu, B., Ouellet, A., Macdonald, P., Jones, M., Collette, R., Chong, P., Fargher, T., St Maurice, F., Fortin, C., Chehayeb, R., Proulx, G., Roy, R., Liutkus, J., Syan, G., Rupka, D., Lichtenstein, T., Kooy, J., Papastergiou, D., Lubelsky, B., Doyle, W., Rajakumar, A., Cha, J., Choudhry, A., Bhamjee, H., Mawji, A., Durfresne, M., Constance, C., Mutrie, J., Najarali, A., Warren, R., Mucha, M., Borts, D., Nord, P., Carrier, S., Dawood, M., Sabe Affaki, G., Archibald, J., Abram, N., Teitelbaum, E., Ebrahim, I., Siebert, R., van Zyl, L., Theron, H., Lloyd, E., Sommers, R., Podgorski, G., Steingo, L., Dalby, A., Bayat, J., Herbst, L., Bester, F., Corbett, C., Bennett, J., Roodt, A., Roux, J., Abelson, M., Mohamed, Z., Nortje, H., Da Silva, A., Nikolaides, K., Liagkas, K., Papasteriadis, E., Achimastos, A., Koliopoulos, N., Trikas, A., Manolis, A., Ruiter, J., Basart, D., Crijns, H., Withagen, A., Janssen, M., Van Langeveld, R., van Gelder, I., Hamer, B., Van Der Heijden, R., Hertzeberger, D., Van Hessen, M., Pieterse, M., Groutars, R., Kuijper, A., De Ruiter, G., van Boven, A., Hoogslag, P., Kragten, H., Thijssen, H., Veldkamp, R., Scavee, C., Heidbuchel, H., Debruyne, P., Deruyter, B., El Ali, H., Goethals, M., Cytryn, R., Striekwold, H., De Wolf, L., Goethals, P., Provenier, F., Hellemans, S., Galinier, M., Coisne, D., Koenig, A., Galley, D., Destrac, S., Leduc, J., Rifai, A., Citron, B., Ellie, E., Fournier, P., Steg, G., Landel, R., Robinson, A., Ziegler, F., Boulliat, J., Zuber, M., Vida, M., Galve Basilio, E., Lopez, M., Íñiguez, C., Iglesias Alonso, L., Cavero Gibanel, M., Olivan Martinez, J., Calvo Iglesias, F., Marco Vera, P., Bruguera Cortada, J., Jaber Houbani, A., Merino, J., Olaz Preciado, F., Balaguer, J., de la Hera Galarza, J., Martinez Rubio, A., Fontcuberta, J., Sotillo Marti, J., Gonzalez Juanatey, J., Del Campo, R., Vivanco, G., Alvarez Garcia, P., Pelayo, M., Lippai, J., Zamolyi, K., Károly, T., Vertes, A., Nagy, A., Kosa, I., Janosi, A., Lupkovics, G., Kalo, E., Forster, T., Kis, E., Tenczer, J., Bereczki, D., Komoly, S., Csanyi, A., Kiss, R., Valikovics, A., Dioszeghy, P., Masini, F., Terrosu, P., Cirrincione, V., Marabotti, C., Cosmi, F., Salvioni, A., Binetti, G., Piovaccari, G., Nassiacos, D., Boriani, Giuseppe, Calvi, V., De Caterina, R., Pengo, V., Parati, G., Carolei, A., D'Angelo, A., Di Biase, M., Fattore, L., Agnelli, G., Merlini, P., Furlan, M., Rasura, M., Gandolfo, C., Ageno, W., Piovella, F., Micieli, G., Cinteza, M., Fierbinteanu, C., Natase Melicovici, D., Ionescu, D., Macarie, C., Nanea, I., Radoi, M., Tatu Chitoiu, G., Dragulescu, S., Tudose, A., Militaru, C., Bengus, C., Ungureanu, G., Tau, A., Popa, V., Pirvu, O., Bojinca, M., Sipciu, D., Popescu, M., Chiru, M., Vinereanu, D., Tudoran, M., Cojocaru, T., Vintila, M., Aron, G., Petrascu, O., Bolohan, F., Baumgartner, R., Sekoranja, L., Vojacek, J., Lacnak, B., Kellnerova, I., Dunaj, M., Cihalik, C., Janota, T., Janousek, J., Bouchal, P., Spacek, R., Choi Siruckova, J., Heinc, P., Vojtisek, P., Pirchala, M., Malecha, J., Padour, F., Linhart, A., Mandysova, E., Jandik, J., Zidkova, E., Sipula, D., Ostadal, P., Polasek, R., Stransky, V., Marcinek, G., Rysava, D., Osmancik, P., Huber, K., Drexel, H., Brainin, M., Eichinger Hasenauer, S., Lang, W., Pilger, E., Moriarty, A., Hudson, I., Tang, K., Cleland, J., Macwalter, R., Cooke, J., Mcinnes, G., Durairaj, R., Macleod, M., Murdoch, D., Kadr, H., Lip, G., Andrews, R., Hunt, B., Jackson, P., Roffe, C., Syed, H., Bath, P., Coyle, J., Kelly, D., Stender, S., Torppedersen, C., Tuxen, C., Jensen, G., Melchior, T., Klarlund, K., Dahlstrom, C., Nielsen, T., Nielsen, E., Bronnum Schou, J., Sykulski, R., Blomstrom, P., Lindholm, C., Wallen, T., Nilsson, C., Bertholds, E., Carlsater, J., Sirnes, P., Elle, S., Risberg, K., Furuseth, K., Skag, A., Hoivik, H., Landmark, N., Kjaernli, T., Berg Johansen, J., Gradek, G., Drzewiecki, A., Pluta, W., Szwed, H., Trusz Gluza, M., Ogorek, M., Loboz Grudzien, K., Ruszkowski, P., Sciborski, R., Kopaczewski, J., Jaworska, K., Kubica, J., Opolski, G., Hoffman, A., Krzciuk, M., Sinkiewicz, W., Piotrowski, W., Kolodziej, P., Goszczynska, M., Rynkiewicz, A., Chojnowska, L., Lewczuk, J., Biedrzycka, M., Piepiorka, M., Kowal, J., Karczmarczyk, A., Pruszczyk, P., Tendera, M., Gaciong, Z., Krzeminska Pakula, M., Kornacewicz Jach, Z., Kania, G., Brachmann, J., Lawall, H., Guelker, H., Spitzer, S., Moebiuswinkler, S., Dempfle, C., Bode, C., Darius, H., Genth Zotz, S., Sommer, S., Roehnisch, J., Strasser, R., Daenschel, W., Schwencke, C., vom Dahl, J., Meuser, M., Behrens Spandau, S., Behrens Humbold, S., Muegge, A., Schoen, N., Grooterhorst, P., Ebert, H., Kraemer, A., Kohler, B., Taggeselle, J., Claus, G., Sarnighausen, H., Al Zoebi, A., Schroeder, T., Weissbrodt, M., Lange, R., Gabelmann, M., Kaeaeb, S., Doerr, M., Boscher, D., Bosch, R., Sonntag, F., Bauknecht, C., Omran, H., Leicht, M., Veltkamp, R., Hohensee, H., Dieckmann, H., Winkelmann, B., Bernhardt, P., Schnabel, A., Kadel, C., Proskynitopoulos, N., Seidl, K., Schellong, S., Rios, C., Guevara, C., Coloma, R., Torrejon, H., Parra Galvan, J., Drago Silva, J., Gallegos, J., Mendoza, A., Negron, S., Watanabe, L., Medina, F., Virgen Carrilo, L., Alvarez Lopez, H., Rodriguez, I., Leiva Pons, J., Baños Velasco, A., Villarreal Careaga, J., De los Rios, M., Alcocer Gamba, M., Llamas Esperon, G., Villeda, E., Ahuad Guerrero, A., Alvariqueta, A., Amuchastegui, M., Bluguermann, J., Caime, G., Cuneo, C., Gabito, A., Garcia Brasca, D., Hominal, M., Jure, H., Luquez, H., Montana, O., Piskorz, D., Listorti, S., Serra, J., Sessa, H., Varini, S., Vita, N., Aiub, J., Mackinnon, I., Chekherdemian, S., Castagnino, J., Cimbaro Canella, J., Sgammini, H., Escudero, A., Albina, G., Rapallo, C., Balparda, C., Chahin, M., Fuentealba, V., Riccitelli, M., Casabe, J., Lobo Marquez, L., Kevorkian, R., Cuadrado, J., Dran, R., Muntaner, J., Gonzalez, M., Cartasegna, L., Hasbani, E., Hrabar, A., Sanchez, A., Vogel, D., Hershson, A., Avezum, A., Jaber, J., Ernesto Leaes, P., Bozza, A., Lorga Filho, A., Pimentel Filho, P., Moura Jorge, J., Maia, L., Manenti, E., D'Aurea Mora, R., de Souza Neto, J., Precoma, D., Rabelo, A., Rocha, J., Rossi, P., Kerr Saraiva, J., Zimerman, L., Bodanese, L., Figueiredo, E., de Souza, W. Sebba Barroso, Braga, J., Alessi, S., Gomes, M., Silva, R., Teixeira, M., Costa, F., Motta, M., Sobral Filho, D., Reis, G., Garbelini, B., Zimmermann, S., Pereira Barretto, A., Dohmann, H., Barreto Filho, J., Ghorayeb, N., Borelli, F., Rossi dos Santos, F., Lopes Prudente, M., Vejar, M., Lanas, F., Del Pino, R., Potthoff, S., Charme, G., Aguirre, A., Saldana, A., Garces, E., Bunster, L., Figueroa, H., Olivares, C., Raffo, C., Vergara, E., Sepulveda, P., Jano, G., Morales Alvarado, J., Suarez, R., Urina, M., Perez, G., Quintero, A., Pava, L., Botero Lopez, R., Luengas, C., Hernandez, E., Sanchez, D., Poveda, C., Coronel, J., Beltran, R., Jaramillo, C., Pardo, J., Ponte Negretti, C., Isea, J., Vergara, G., Morr, I., Sim, K., Wan Ahmad, W., Yusof, Z., Rosman, A., Basri, H., Thompson, P., Jeffery, P., Purnell, I., Roberts Thomson, P., Heddle, W., Waites, J., Walters, D., Amerena, J., Challa, P., Karrasch, J., Lowy, A., Fitzpatrick, D., Parsons, M., Phan, T., Bladin, C., Donnan, G., Aroney, G., Gerraty, R., Anderson, C., Blombery, P., Martin, P., Tissa Wijeratne, K., Cross, D., Crimmins, D., Packham, D., Jackson, D., Chua, W., Merino, R., Magno, M., Tirador, L., Batalla, E., Manalo, C., Uy, N., Ebo, G., Reyes, E., Bernan, A., Richards, M., Hart, H., Mann, S., Fisher, R., Stewart, R., Wilkins, G., Barber, A., Tan, R., Ong, H., Singh, R., Sukonthasarn, A., Tanomsup, S., Krittayaphong, R., Piamsomboon, C., Piyayotai, D., Sunsaneewitayakul, B., Baek, S., Seo, H., Rim, S., Kim, C., Kim, K., Ryu, K., Jo, S., Tahk, S., Lee, H., Kim, Y., Shin, D., Choi, Y., Chung, N., Namgung, J., Hong, T., Shin, W., Jin, S., Yan, X., Fu, G., Lu, G., Yang, K., Xu, D., Chen, J., Liu, J., Wu, S., Song, J., Liao, Y., Xu, B., Li, Z., Ma, S., Yin, Y., Zhao, Y., Hu, D., Ma, C., Ma, J., Sun, J., Li, H., Hong, X., Yu, B., Lu, Q., Yang, J., Wu, Z., Li, Y., Huang, Y., Wang, Y., Liu, M., Cheng, Y., Yang, T., Chen, K., Wang, H., Yuan, Z., Wang, J., Zeng, Z., Chen, Y., Yavuzgil, O., Kozan, O., Etemoglu, M., Diker, E., Belgi, A., Ceyhan, C., Cin, V., Yilmaz, O., Ata, N., Altunkeser, B., Agacdiken Agir, A., Karadede, A., Topsakal, R., Gulati, R., Madhavan, A., Jain, S., Oomman, A., Janorkar, S., Kumar, P., Madhukar Naik, A., Thacker, H., Rajasekhar, V., Reddy, R., Keshavamurthy, C., Jain, P., Gowdappa, B., Gadkari, M., Abhyankar, A., Ramesh Babu, B., Vydianathan, P., Sinha, S., Garg, N., Rao, S., Gautam, P., Chockalingam, K., Kumbla, M., Panwar, R., Banker, D., Kaste, M., Jäkälä, P., Roine, R., Mihov, A., Raev, D., Yordanova, V., Dimitrova, S., Benov, H., Tsanova, V., Kyolean, M., Marchev, S., Stoikov, A., Zdravkov, N., Ramshev, K., Krastev, A., Stamenova, P., Angelova, I., Pencheva, G., Grigorova, V., Petrauskiene, B., Skripkauskiene, I., Raugaliene, R., Norkiene, S., Mazutavicius, R., Kavoliuniene, A., Aidietiene, S., Aganauskiene, J., Dailydkiene, A., Marcinkeviciene, J., Grigoniene, L., Anusauskiene, J., Kavaliauskiene, R., Lizogub, V., Rudenko, L., Tseluyko, V., Voronkov, L., Sychov, O., Svyshchenko, Y., Sirenko, Y., Serkova, V., Seredyuk, N., Pertseva, T., Netyazhenko, V., Lishnevska, V., Kupchynska, O., Koval, O., Koshukova, G., Karpenko, O., Grishyna, O., Faynyk, A., Dzyak, G., Dyadyk, O., Yena, L., Volkov, V., Rudyk, I., Kopytsya, M., Kononenko, L., Amosova, K., Zhurba, S., Kazimirko, V., Iuzkiv, I., Shershnyova, O., Khomazyuk, T., Batushkin, V., Vykhovanyuk, I., Popik, G., Skrebkov, V., Skurtov, A., Mishchenko, T., Lytvynenko, N., Sokolova, L., Vatutin, M., Shved, M., Rebrov, B., Kadina, L., Vajda, M., Ursol, G., Zheleznyy, V., Vysochanska, T., Gozhenko, A., Fan, K., Ho, D., Tse, H., Yu, C., Wong, L., Yeh, H., Pai, P., Hsieh, I., Huang, C., Hsieh, Y., Yin, W., Tsai, L., Huang, T., Chen, C., Chiang, F., Ueng, K., Charng, M., Marmor, A., Katz, A., Butnaru, A., Lewis, B., Eldar, M., Rosenhack, S., Elias, N., Koifman, B., Shochat, M., Swissa, M., Zimlichman, R., Bental, T., Weiss, A., Ganam, R., Elias, M., Nseir, W., Oliven, A., Brenner, B., Dayan, M., Pokorney, S, Piccini, J, Stevens, S, Patel, M, Pieper, K, Halperin, J, Breithardt, G, Singer, D, Hankey, G, Hacke, W, Becker, R, Berkowitz, S, Nessel, C, Mahaffey, K, Fox, K, Califf, R, Parati, G, Neurologian yksikkö, and Clinicum

Subjects
Male, Time Factors, medicine.medical_treatment, Administration, Oral, Comorbidity, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, THERAPY, Sudden Cardiac Death, 3124 Neurology and psychiatry, Sudden cardiac death, 0302 clinical medicine, Rivaroxaban, Risk Factors, Cause of Death, Atrial Fibrillation, 80 and over, Medicine, Arrhythmia and Electrophysiology, atrial fibrillation, 030212 general & internal medicine, Stroke, Cause of death, Original Research, CATHETER ABLATION, Aged, 80 and over, DABIGATRAN, Age Factors, Atrial fibrillation, 3. Good health, Intention to Treat Analysis, Treatment Outcome, Mortality, Warfarin, Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Factor Xa Inhibitors, Female, Humans, Multivariate Analysis, Proportional Hazards Models, Risk Assessment, Sex Factors, Cardiology and Cardiovascular Medicine, Administration, medicine.drug, Oral, medicine.medical_specialty, Catheter ablation, Dabigatran, 03 medical and health sciences, RISK-FACTOR, Intensive care medicine, METAANALYSIS, Ischemic Stroke, Intracranial Hemorrhage, Heart Failure, CONGESTIVE-HEART-FAILURE, business.industry, EFFICACY, medicine.disease, warfarin, Emergency medicine, FOLLOW-UP, business
Abstract

Background Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all‐cause mortality may guide interventions. Methods and Results In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study, patients with nonvalvular atrial fibrillation were randomized to rivaroxaban or dose‐adjusted warfarin. Cox proportional hazards regression with backward elimination identified factors at randomization that were independently associated with all‐cause mortality in the 14 171 participants in the intention‐to‐treat population. The median age was 73 years, and the mean CHADS 2 score was 3.5. Over 1.9 years of median follow‐up, 1214 (8.6%) patients died. Kaplan–Meier mortality rates were 4.2% at 1 year and 8.9% at 2 years. The majority of classified deaths (1081) were cardiovascular (72%), whereas only 6% were nonhemorrhagic stroke or systemic embolism. No significant difference in all‐cause mortality was observed between the rivaroxaban and warfarin arms ( P =0.15). Heart failure (hazard ratio 1.51, 95% CI 1.33–1.70, P CI 1.51–1.90, P Conclusions In a large population of patients anticoagulated for nonvalvular atrial fibrillation, ≈7 in 10 deaths were cardiovascular, whereas Clinical Trial Registration URL : https://www.clinicaltrials.gov/ . Unique identifier: NCT 00403767.

Published
2016

9. 663TiP - A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study

Author

Barbera, M.A., Corbelli, J., Papiani, G., Grassi, E., Ugolini, G., Montroni, I., Bartolomeo, M Di, Cascinu, S., Marzola, M., Bonetti, A., Frassineti, G.L., Nanni, O., Zattoni, D., Ghignone, F., Taffurelli, G., Pinto, C., Moretti, C Carli, Rossi, G., Palazzi, S., and Tamberi, S.

Published
2019
Full Text
View/download PDF

10. Metronomic capecitabine in advanced hepatocellualr cacinoma patients who have failed sorafenib: a phase II study

Author

De Rosa F, Di Girolamo S, Corbelli J, Longobardi C, Agostini V, Andreone P, Serra C, Piscaglia F, Trevisani F, Golfieri R, Bolondi L, Pinna AD, Biasco G, Brandi G, and De Rosa F, Di Girolamo S, Corbelli J, Longobardi C, Agostini V, Andreone P, Serra C, Piscaglia F, Trevisani F, Golfieri R, Bolondi L, Pinna AD, Biasco G, Brandi G

Subjects
Metronomic chemotherapy, sorafenib, advanced hepatocellular carcinoma, antiangiogenic activity
Published
2011

11. Metronomic capecitabine in advanced hepatocellular carcinoma patients who have failed sorafenib: a phase 2 study

Author

de Rosa F, Di Girolamo S, Corbelli J, Longobardi C, Agostini V, Andreone P, Serra C, PISCAGLIA, FABIO, TREVISANI, FRANCO, Golfieri R, BOLONDI, LUIGI, PINNA, ANTONIO DANIELE, BIASCO, GUIDO, BRANDI, GIOVANNI, de Rosa F, Di Girolamo S, Corbelli J, Longobardi C, Agostini V, Andreone P, Serra C, Piscaglia F, Trevisani F, Golfieri R, Bolondi L, Pinna AD, Biasco G, and Brandi G.

Published
2011

12. The follow-up issues: from the necessity to the opportunity

Author

BRANDI, GIOVANNI, LONGOBARDI, CIRO, DE ROSA, FRANCESCO, AGOSTINI, VALENTINA, MACCHINI, MARINA, NANNINI, MARGHERITA, Maleddu A, SAPONARA, MARISTELLA, Di Tullio P, Degli Esposti C, Katzinas J, Di Girolamo S, Rubino D, Pini S, Pallotti M, Paragona M, Lolli C, Corbelli J, GARAJOVA, INGRID, Vecchiarelli S, Mandrioli A, Zucchini G, PANTALEO, MARIA ABBONDANZA, DI MARCO, MARIACRISTINA, CUCCHETTI, ALESSANDRO, BIASCO, GUIDO, Brandi G, Nannini M, Longobardi C, Maleddu A, Saponara M, Di Tullio P, Degli Esposti C, Katzinas J, Di Girolamo S, de Rosa F, Agostini V, Macchini M, Rubino D, Pini S, Pallotti M, Paragona M, Lolli C, Corbelli J, Garajovà I, Vecchiarelli S, Mandrioli A, Zucchini G, Pantaleo MA, Di Marco M, Cucchetti A, and Biasco G.

Published
2011

13. Rapid, marked wash out at contrast-enhanced ultrasound in nodules in cirrhosis should raise the suspicion of cholangiocarcinoma

Author

Galassi M, Piscaglia F, Lucidi V, Renzulli M, Cescon M, Venerandi L, Corbelli J, Vasuri F, Golfieri R, Bolondi L, and Galassi M, Piscaglia F, Lucidi V, Renzulli M, Cescon M, Venerandi L, Corbelli J, Vasuri F, Golfieri R, Bolondi L

Subjects
Cholangiocarcinoma, misdiagnosing, CEUS, Hepatocellular Carcinoma, Contrast Enhanced Ultrasound, HCC, CCC
Published
2011

14. Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

Author

Pokorney, Sean D., primary, Piccini, Jonathan P., additional, Stevens, Susanna R., additional, Patel, Manesh R., additional, Pieper, Karen S., additional, Halperin, Jonathan L., additional, Breithardt, Günter, additional, Singer, Daniel E., additional, Hankey, Graeme J., additional, Hacke, Werner, additional, Becker, Richard C., additional, Berkowitz, Scott D., additional, Nessel, Christopher C., additional, Mahaffey, Kenneth W., additional, Fox, Keith A. A., additional, Califf, Robert M., additional, Anderson, J., additional, Bedwell, N., additional, Bilsker, M., additional, Bruce, G., additional, Agah, R., additional, DeSantis, M., additional, Eisenberg, S., additional, Flores, A., additional, Herzog, W., additional, Klein, S., additional, Snyder, H., additional, Krueger, S., additional, Almaguer, E., additional, Lavie, E., additional, Lee, C., additional, Mallis, G., additional, Modi, M., additional, Woodworth, G., additional, Niazi, I., additional, Peart, B., additional, Sundaram, S., additional, Snoddy, B., additional, Sotolongo, R., additional, Moloney, J., additional, Vijayaraghavan, K., additional, Whittier, F., additional, Yellen, L., additional, Banerjee, S., additional, Lustgarten, D., additional, Suresh, D., additional, Gelernt, M., additional, Levinson, L., additional, Ghanekar, R., additional, Kneller, G., additional, Hall, C., additional, Fadl, Y., additional, Pirwitz, M., additional, French, W., additional, Mayer, N., additional, Pugeda, J., additional, Steel, K., additional, Mody, F., additional, Malik, A., additional, Chandna, H., additional, Go, A., additional, Emlein, G., additional, Bowden, W., additional, Moscoso, R., additional, Hodson, R., additional, Berk, M., additional, Pan, D., additional, Pappas, J., additional, Orchard, R., additional, Lynchard, G., additional, Vijay, N., additional, Khan, W., additional, El Khadra, M, additional, Antonishen, M., additional, Cucher, F., additional, Staab, M., additional, Zebrack, J., additional, Borromeo, S, additional, Heilman, J., additional, Chaturvedi, S., additional, Makam, S., additional, Turk, S., additional, Hyers, T., additional, Williams, G., additional, Labroo, A., additional, Gill, S., additional, Myears, D., additional, Weinstein, J., additional, Shanes, J., additional, Chandrashekhar, Y., additional, Shah, S., additional, Reiter, W., additional, Logemann, T., additional, Almquist, A., additional, Bhagwat, R., additional, Tak, T., additional, Shen‐Ling, J., additional, Patel, P., additional, Artis, A., additional, Arouni, A., additional, Lauer, M., additional, Kinney, K., additional, Elsen, J., additional, Roan, P., additional, Villafria, R., additional, Sumpter, M., additional, Ip, J., additional, Welka, S., additional, Schifferdecker, B., additional, Sandoval, R., additional, Speirs, S., additional, Jones, A., additional, Haldis, T., additional, Kazmierski, J., additional, Sutherland, J., additional, Dietrich, D., additional, Telfer, E., additional, Berry, J., additional, McElveen, A., additional, Russell, J., additional, Sackett, M., additional, Antonios, N., additional, Smith, D., additional, Vora, K., additional, Kirby, A., additional, Lui, H., additional, Mego, D., additional, Ziada, K., additional, Navas, J., additional, Taussig, A., additional, Koren, M., additional, Vogel, C., additional, Saba, F., additional, Parrott, C., additional, Schneider, R., additional, Shirwany, A., additional, Rubin, M., additional, Treasure, C, additional, Bertolet, B., additional, Chang, M., additional, Langberg, J., additional, Becker, R., additional, Cohen, Y., additional, McGrew, F., additional, White, J., additional, Arzola, F., additional, Zelenka, J., additional, Tannenbaum, A., additional, Fernandes, V., additional, Jamnadas, P., additional, Agamasu, J., additional, Collins, B., additional, Jauch, W., additional, Sasseen, B., additional, Hotchkiss, D., additional, Abadier, R., additional, Osunkoya, A., additional, Schlau, A., additional, Chappel, C., additional, Foster, M., additional, Braun, E., additional, Mostel, E., additional, Capo, J., additional, Ashchi, M., additional, Howard, V., additional, Albirini, A., additional, Burger, A., additional, Rolston, D., additional, Staniloae, C., additional, Bacon, J., additional, Wiseman, A., additional, McGarvey, J, additional, Sonel, A., additional, Hamroff, G., additional, Chang, D., additional, Daboul, N., additional, Broderick, G., additional, Meholick, A., additional, Corbelli, J., additional, Silverman, R., additional, Raffetto, J., additional, Fishberg, R., additional, Georgeson, S., additional, Held, J., additional, Seidner, M., additional, Saint‐Jacques, H., additional, Heitner, J., additional, Kutalek, S., additional, Friedlander, I., additional, Hutchinson, B., additional, Walia, J., additional, Kondo, N., additional, Smiley, N., additional, Blitz, L., additional, Dale, H., additional, Sulman, S., additional, Szulawski, I., additional, Modares, F., additional, Martin, R., additional, Nahhas, A., additional, Renzi, M., additional, Akyea‐Djamson, A., additional, Alfieri, A., additional, Sandhu, J., additional, Voyce, S., additional, Amaram, S., additional, Meyerrose, G., additional, Shoukfeh, M., additional, Lee, F., additional, Villegas, B., additional, Idowu, O., additional, Khera, A., additional, Sam, C., additional, Vo, A., additional, Lieber, I., additional, Smith, T., additional, Awan, N., additional, Tsai, C., additional, Ganim, R., additional, Alzaghrini, G., additional, Pitt, W., additional, Shepherd, A., additional, Tang, S., additional, Stoltz, S., additional, Nelson, W., additional, Cox, S., additional, Meymandi, S., additional, Melucci, M., additional, Thomas, G., additional, Gogia, H., additional, Machell, C., additional, Chandrasekaran, S., additional, Brown, C., additional, Jetty, P., additional, Miller, G., additional, Dykstra, G., additional, Jaffrani, N., additional, Zakhary, B., additional, Caruso, A., additional, Zolty, R., additional, Fox, D., additional, Jacobs, G., additional, Lebenthal, M., additional, Mukherjee, S., additional, Zimetbaum, P., additional, Kingsley, J., additional, Jones, R., additional, Robinson, V., additional, Kenton, D., additional, Usedom, J., additional, Williams, S., additional, Snipes, C., additional, Wilson, V., additional, Hasty, R., additional, Shoemaker, J., additional, Donahue, M., additional, Al‐Saghir, Y., additional, Thomsen, E., additional, Yarows, S., additional, Chastain, S., additional, McLaughlin, P., additional, Wakham, M., additional, Shrestha, D., additional, Simmons, J., additional, Fisher, D., additional, Seymour, Z., additional, Frandsen, B., additional, First, B., additional, Sharpe, C., additional, Popeil, L., additional, Guthrie, R., additional, Hunter, J., additional, Alvarado, O., additional, Sandberg, J., additional, Gutman, N., additional, Belber, A., additional, Arkhipov, M., additional, Ballyzek, M., additional, Baranov, A., additional, Barbarash, O., additional, Barbarich, V., additional, Belenky, D., additional, Berkovich, O., additional, Bokarev, I., additional, Boyarkin, M., additional, Vaniev, S., additional, Volkova, E., additional, Gratsiansky, N., additional, Demin, A., additional, Zadionchenko, V., additional, Zateyshchikov, D., additional, Zrazhevsky, K., additional, Mazaev, V., additional, Martynov, A., additional, Mikhailov, S., additional, Mkrtchian, V., additional, Novozhenov, V., additional, Raskina, T., additional, Rebrov, A., additional, Sanina, N., additional, Simanekov, V., additional, Sitnikova, M., additional, Smolenskaya, O., additional, Stryuk, R., additional, Storozhakov, G., additional, Tankhilevich, B., additional, Tereschenko, S., additional, Khokhlov, A., additional, Khrustalev, O., additional, Chernov, S., additional, Shvarts, Y., additional, Shubik, Y., additional, Shulman, V., additional, Yakushin, S., additional, Bugrova, O., additional, Ivleva, A., additional, Libis, R., additional, Khozyainova, N., additional, Maslov, S., additional, Baranova, E., additional, Sherenkov, A., additional, Libov, I., additional, Lusov, V., additional, Chumakova, G., additional, Kuznetsov, V., additional, Ryamzina, I., additional, Reshetko, O., additional, Boldueva, S., additional, Alekseeva, N., additional, Novikova, T., additional, Dvornikov, V., additional, Idrisova, E., additional, Shostak, N., additional, Yarokhno, N., additional, Tebloev, K., additional, Treshkur, T., additional, Mazurov, V., additional, Loktin, E., additional, Sedavnyh, I., additional, Alexeeva, O., additional, Yakhontova, P., additional, Repin, A., additional, Izmozherova, N., additional, Kostenko, V., additional, Fokin, A., additional, Ketova, G., additional, Kouz, S., additional, Leader, R., additional, Ayala‐Paredes, F., additional, Luton, R., additional, Ma, P., additional, Pandey, S., additional, Pesant, Y., additional, Senior, R., additional, Vertes, G., additional, Bell, A., additional, Crowley, D., additional, Vizel, S., additional, Lasko, B., additional, Landry, D., additional, Berger, L., additional, Heath, J., additional, Bessoudo, R., additional, Ling, M., additional, Tellier, G., additional, Berlingieri, J., additional, Kafka, H., additional, Hill, L., additional, Mazza, G., additional, O'Mahony, W., additional, Chilvers, M., additional, O'Mahony, M., additional, Newman, D., additional, Silagy, S., additional, Heffernan, M., additional, Bennett, M., additional, Bhesania, T., additional, Rockman, G., additional, Ng, K., additional, Kalra, B., additional, Meneses, G., additional, Liang, W., additional, Cheung, M., additional, Kozak, J., additional, Pugen, G., additional, Vavougios, J., additional, Kates, M., additional, Nunes‐Vaz, C., additional, Jaffer, S., additional, Orfi, J., additional, Faiers, A., additional, Chung, C., additional, Felsen, S., additional, Bergman, S., additional, Bernstein, I., additional, Brownscombe, L., additional, Stockdill, J., additional, Silver, E., additional, Ezekiel, D., additional, Jagan, N., additional, Khurana, M., additional, Reisler, H., additional, Goldman, H., additional, Maung, T., additional, Wong, F., additional, Gillis, G., additional, Vexler, R., additional, Goldberg, B., additional, Luterman, M., additional, Gould, D., additional, Coutu, B., additional, Ouellet, A., additional, MacDonald, P., additional, Jones, M., additional, Collette, R., additional, Chong, P., additional, Fargher, T., additional, St‐Maurice, F., additional, Fortin, C., additional, Chehayeb, R., additional, Proulx, G., additional, Roy, R., additional, Liutkus, J., additional, Syan, G., additional, Rupka, D., additional, Lichtenstein, T., additional, Kooy, J., additional, Papastergiou, D., additional, Lubelsky, B., additional, Doyle, W., additional, Rajakumar, A., additional, Cha, J., additional, Choudhry, A., additional, Bhamjee, H., additional, Mawji, A., additional, Durfresne, M., additional, Constance, C., additional, Mutrie, J., additional, Najarali, A., additional, Warren, R., additional, Mucha, M., additional, Borts, D., additional, Nord, P., additional, Carrier, S., additional, Dawood, M., additional, Sabe‐Affaki, G., additional, Archibald, J., additional, Abram, N., additional, Teitelbaum, E., additional, Ebrahim, I., additional, Siebert, R., additional, van Zyl, L., additional, Theron, H., additional, Lloyd, E., additional, Sommers, R., additional, Podgorski, G., additional, Steingo, L., additional, Dalby, A., additional, Bayat, J., additional, Herbst, L., additional, Bester, F., additional, Corbett, C., additional, Bennett, J., additional, Roodt, A., additional, Roux, J., additional, Abelson, M., additional, Mohamed, Z., additional, Nortje, H., additional, Da Silva, A., additional, Nikolaides, K., additional, Liagkas, K., additional, Papasteriadis, E., additional, Achimastos, A., additional, Koliopoulos, N., additional, Trikas, A., additional, Manolis, A., additional, Ruiter, J., additional, Basart, D., additional, Crijns, H., additional, Withagen, A., additional, Janssen, M., additional, Van Langeveld, R, additional, van Gelder, I., additional, Hamer, B., additional, Van Der Heijden, R, additional, Hertzeberger, D., additional, Van Hessen, M, additional, Pieterse, M., additional, Groutars, R., additional, Kuijper, A., additional, De Ruiter, G, additional, van Boven, A., additional, Hoogslag, P., additional, Kragten, H., additional, Thijssen, H., additional, Veldkamp, R., additional, Scavee, C., additional, Heidbuchel, H., additional, Debruyne, P., additional, Deruyter, B., additional, El Ali, H, additional, Goethals, M., additional, Cytryn, R., additional, Striekwold, H., additional, De Wolf, L, additional, Goethals, P., additional, Provenier, F., additional, Hellemans, S., additional, Galinier, M., additional, Coisne, D., additional, Koenig, A., additional, Galley, D., additional, Destrac, S., additional, Leduc, J., additional, Rifai, A., additional, Citron, B., additional, Ellie, E., additional, Fournier, P., additional, Steg, G., additional, Landel, R., additional, Robinson, A., additional, Ziegler, F., additional, Boulliat, J., additional, Zuber, M., additional, Vida, M., additional, Galve Basilio, E., additional, Lopez, M., additional, Íñiguez, C., additional, Iglesias Alonso, L., additional, Cavero Gibanel, M., additional, Olivan Martinez, J., additional, Calvo Iglesias, F., additional, Marco Vera, P., additional, Bruguera Cortada, J., additional, Jaber Houbani, A., additional, Merino, J., additional, Olaz Preciado, F., additional, Balaguer, J., additional, de la Hera Galarza, J, additional, Martinez Rubio, A., additional, Fontcuberta, J., additional, Sotillo Marti, J., additional, Gonzalez Juanatey, J., additional, Del Campo, R., additional, Vivanco, G., additional, Alvarez Garcia, P., additional, Pelayo, M., additional, Lippai, J., additional, Zamolyi, K., additional, Károly, T., additional, Vertes, A., additional, Nagy, A., additional, Kosa, I., additional, Janosi, A., additional, Lupkovics, G., additional, Kalo, E., additional, Forster, T., additional, Kis, E., additional, Tenczer, J., additional, Bereczki, D., additional, Komoly, S., additional, Csanyi, A., additional, Kiss, R., additional, Valikovics, A., additional, Dioszeghy, P., additional, Masini, F., additional, Terrosu, P., additional, Cirrincione, V., additional, Marabotti, C., additional, Cosmi, F., additional, Salvioni, A., additional, Binetti, G., additional, Piovaccari, G., additional, Nassiacos, D., additional, Boriani, G., additional, Calvi, V., additional, De Caterina, R, additional, Pengo, V., additional, Parati, G., additional, Carolei, A., additional, D'Angelo, A., additional, Di Biase, M., additional, Fattore, L., additional, Agnelli, G., additional, Merlini, P., additional, Furlan, M., additional, Rasura, M., additional, Gandolfo, C., additional, Ageno, W., additional, Piovella, F., additional, Micieli, G., additional, Cinteza, M., additional, Fierbinteanu, C., additional, Natase‐Melicovici, D., additional, Ionescu, D., additional, Macarie, C., additional, Nanea, I., additional, Radoi, M., additional, Tatu‐Chitoiu, G., additional, Dragulescu, S., additional, Tudose, A., additional, Militaru, C., additional, Bengus, C., additional, Ungureanu, G., additional, Tau, A., additional, Popa, V., additional, Pirvu, O., additional, Bojinca, M., additional, Sipciu, D., additional, Popescu, M., additional, Chiru, M., additional, Vinereanu, D., additional, Tudoran, M., additional, Cojocaru, T., additional, Vintila, M., additional, Aron, G., additional, Petrascu, O., additional, Bolohan, F., additional, Baumgartner, R., additional, Sekoranja, L., additional, Vojacek, J., additional, Lacnak, B., additional, Kellnerova, I., additional, Dunaj, M., additional, Cihalik, C., additional, Janota, T., additional, Janousek, J., additional, Bouchal, P., additional, Spacek, R., additional, Choi Siruckova, J., additional, Heinc, P., additional, Vojtisek, P., additional, Pirchala, M., additional, Malecha, J., additional, Padour, F., additional, Linhart, A., additional, Mandysova, E., additional, Jandik, J., additional, Zidkova, E., additional, Sipula, D., additional, Ostadal, P., additional, Polasek, R., additional, Stransky, V., additional, Marcinek, G., additional, Rysava, D., additional, Osmancik, P., additional, Huber, K., additional, Drexel, H., additional, Brainin, M., additional, Eichinger‐Hasenauer, S., additional, Lang, W., additional, Pilger, E., additional, Moriarty, A., additional, Hudson, I., additional, Tang, K., additional, Cleland, J., additional, MacWalter, R., additional, Cooke, J., additional, McInnes, G., additional, Durairaj, R., additional, MacLeod, M., additional, Murdoch, D., additional, Kadr, H., additional, Lip, G., additional, Andrews, R., additional, Hunt, B., additional, Jackson, P., additional, Roffe, C., additional, Syed, H., additional, Bath, P., additional, Coyle, J., additional, Kelly, D., additional, Stender, S., additional, TorpPedersen, C., additional, Tuxen, C., additional, Jensen, G., additional, Melchior, T., additional, Klarlund, K., additional, Dahlstrom, C., additional, Nielsen, T., additional, Nielsen, E., additional, Bronnum‐Schou, J., additional, Sykulski, R., additional, Blomstrom, P., additional, Lindholm, C., additional, Wallen, T., additional, Nilsson, C., additional, Bertholds, E., additional, Carlsater, J., additional, Sirnes, P., additional, Elle, S., additional, Risberg, K., additional, Furuseth, K., additional, Skag, A., additional, Hoivik, H., additional, Landmark, N., additional, Kjaernli, T., additional, Berg‐Johansen, J., additional, Gradek, G., additional, Drzewiecki, A., additional, Pluta, W., additional, Szwed, H., additional, Trusz‐Gluza, M., additional, Ogorek, M., additional, Loboz‐Grudzien, K., additional, Ruszkowski, P., additional, Sciborski, R., additional, Kopaczewski, J., additional, Jaworska, K., additional, Kubica, J., additional, Opolski, G., additional, Hoffman, A., additional, Krzciuk, M., additional, Sinkiewicz, W., additional, Piotrowski, W., additional, Kolodziej, P., additional, Goszczynska, M., additional, Rynkiewicz, A., additional, Chojnowska, L., additional, Lewczuk, J., additional, Biedrzycka, M., additional, Piepiorka, M., additional, Kowal, J., additional, Karczmarczyk, A., additional, Pruszczyk, P., additional, Tendera, M., additional, Gaciong, Z., additional, Krzeminska‐Pakula, M., additional, Kornacewicz‐Jach, Z., additional, Kania, G., additional, Brachmann, J., additional, Lawall, H., additional, Guelker, H., additional, Spitzer, S., additional, MoebiusWinkler, S., additional, Dempfle, C., additional, Bode, C., additional, Darius, H., additional, Genth‐Zotz, S., additional, Sommer, S., additional, Roehnisch, J., additional, Strasser, R., additional, Daenschel, W., additional, Schwencke, C., additional, vom Dahl, J, additional, Meuser, M., additional, Behrens‐Spandau, S., additional, Behrens‐Humbold, S., additional, Muegge, A., additional, Schoen, N., additional, Grooterhorst, P., additional, Ebert, H., additional, Kraemer, A., additional, Kohler, B., additional, Taggeselle, J., additional, Claus, G., additional, Sarnighausen, H., additional, Al‐Zoebi, A., additional, Schroeder, T., additional, Weissbrodt, M., additional, Lange, R., additional, Gabelmann, M., additional, Kaeaeb, S., additional, Doerr, M., additional, Boscher, D., additional, Bosch, R., additional, Sonntag, F., additional, Bauknecht, C., additional, Omran, H., additional, Leicht, M., additional, Veltkamp, R., additional, Hohensee, H., additional, Dieckmann, H., additional, Winkelmann, B., additional, Bernhardt, P., additional, Schnabel, A., additional, Kadel, C., additional, Proskynitopoulos, N., additional, Seidl, K., additional, Schellong, S., additional, Rios, C., additional, Guevara, C., additional, Coloma, R., additional, Torrejon, H., additional, Parra Galvan, J., additional, Drago Silva, J., additional, Gallegos, J., additional, Mendoza, A., additional, Negron, S., additional, Watanabe, L., additional, Medina, F., additional, Virgen Carrilo, L., additional, Alvarez Lopez, H., additional, Rodriguez, I., additional, Leiva‐Pons, J., additional, Baños Velasco, A., additional, Villarreal‐Careaga, J., additional, De los Rios, M, additional, Gamba, M., additional, Llamas Esperon, G., additional, Villeda, E., additional, Ahuad Guerrero, A., additional, Alvariqueta, A., additional, Amuchastegui, M., additional, Bluguermann, J., additional, Caime, G., additional, Cuneo, C., additional, Gabito, A., additional, Garcia Brasca, D., additional, Hominal, M., additional, Jure, H., additional, Luquez, H., additional, Montana, O., additional, Piskorz, D., additional, Listorti, S., additional, Serra, J., additional, Sessa, H., additional, Varini, S., additional, Vita, N., additional, Aiub, J., additional, MacKinnon, I., additional, Chekherdemian, S., additional, Castagnino, J., additional, Cimbaro Canella, J., additional, Sgammini, H., additional, Escudero, A., additional, Albina, G., additional, Rapallo, C., additional, Balparda, C., additional, Chahin, M., additional, Fuentealba, V., additional, Riccitelli, M., additional, Casabe, J., additional, Lobo Marquez, L., additional, Kevorkian, R., additional, Cuadrado, J., additional, Dran, R., additional, Muntaner, J., additional, Gonzalez, M., additional, Cartasegna, L., additional, Hasbani, E., additional, Hrabar, A., additional, Sanchez, A., additional, Vogel, D., additional, Hershson, A., additional, Avezum, A., additional, Jaber, J., additional, Ernesto Leaes, P., additional, Bozza, A., additional, Lorga Filho, A., additional, Pimentel Filho, P., additional, Moura Jorge, J., additional, Maia, L., additional, Manenti, E., additional, D'Aurea Mora, R, additional, de Souza Neto, J, additional, Precoma, D., additional, Rabelo, A., additional, Rocha, J., additional, Rossi, P., additional, Kerr Saraiva, J., additional, Zimerman, L., additional, Bodanese, L., additional, Figueiredo, E., additional, de Souza, W. Sebba Barroso, additional, Braga, J., additional, Alessi, S., additional, Gomes, M., additional, Silva, R., additional, Teixeira, M., additional, Costa, F., additional, Motta, M., additional, Sobral Filho, D., additional, Reis, G., additional, Garbelini, B, additional, Zimmermann, S., additional, Pereira Barretto, A., additional, Dohmann, H., additional, Barreto Filho, J., additional, Ghorayeb, N., additional, Borelli, F., additional, Rossi dos Santos, F., additional, Lopes Prudente, M., additional, Vejar, M., additional, Lanas, F., additional, Del Pino, R., additional, Potthoff, S., additional, Charme, G., additional, Aguirre, A., additional, Saldana, A., additional, Garces, E., additional, Bunster, L., additional, Figueroa, H., additional, Olivares, C., additional, Raffo, C., additional, Vergara, E., additional, Sepulveda, P., additional, Jano, G., additional, Morales Alvarado, J., additional, Suarez, R., additional, Urina, M., additional, Perez, G., additional, Quintero, A., additional, Pava, L., additional, Botero Lopez, R., additional, Luengas, C., additional, Hernandez, E., additional, Sanchez, D., additional, Poveda, C., additional, Coronel, J., additional, Beltran, R., additional, Jaramillo, C., additional, Pardo, J., additional, Ponte Negretti, C., additional, Isea, J., additional, Vergara, G., additional, Morr, I., additional, Sim, K., additional, Wan Ahmad, W., additional, Yusof, Z., additional, Rosman, A., additional, Basri, H, additional, Thompson, P., additional, Jeffery, I., additional, Purnell, P., additional, Roberts‐Thomson, P., additional, Heddle, W., additional, Waites, J., additional, Walters, D., additional, Amerena, J., additional, Challa, P., additional, Karrasch, J., additional, Lowy, A., additional, Fitzpatrick, D., additional, Parsons, M., additional, Phan, T., additional, Bladin, C., additional, Donnan, G., additional, Aroney, G., additional, Gerraty, R., additional, Anderson, C., additional, Blombery, P., additional, Martin, P., additional, Tissa Wijeratne, K., additional, Cross, D., additional, Crimmins, D., additional, Packham, D., additional, Jackson, D., additional, Chua, W., additional, Merino, R., additional, Magno, M., additional, Tirador, L., additional, Batalla, E., additional, Manalo, C., additional, Uy, N., additional, Ebo, G., additional, Reyes, E., additional, Bernan, A., additional, Richards, M., additional, Hart, H., additional, Mann, S., additional, Fisher, R., additional, Stewart, R., additional, Wilkins, G., additional, Barber, A., additional, Tan, R., additional, Ong, H., additional, Singh, R., additional, Sukonthasarn, A., additional, Tanomsup, S., additional, Krittayaphong, R., additional, Piamsomboon, C., additional, Piyayotai, D., additional, Sunsaneewitayakul, B., additional, Baek, S., additional, Seo, H., additional, Rim, S., additional, Kim, C., additional, Kim, K., additional, Ryu, K., additional, Jo, S., additional, Tahk, S., additional, Lee, H., additional, Kim, Y., additional, Shin, D., additional, Choi, Y., additional, Chung, N., additional, Namgung, J., additional, Hong, T., additional, Shin, W., additional, Jin, S., additional, Yan, X., additional, Fu, G., additional, Lu, G., additional, Yang, K., additional, Xu, D., additional, Chen, J., additional, Liu, J., additional, Wu, S., additional, Song, J., additional, Liao, Y., additional, Xu, B., additional, Li, Z., additional, Ma, S., additional, Yin, Y., additional, Zhao, Y., additional, Hu, D., additional, Ma, C., additional, Ma, J., additional, Sun, J., additional, Li, H., additional, Hong, X., additional, Yu, B., additional, Lu, Q., additional, Yang, J., additional, Wu, Z., additional, Li, Y., additional, Huang, Y., additional, Wang, Y., additional, Liu, M., additional, Cheng, Y., additional, Yang, T., additional, Chen, K., additional, Wang, H., additional, Yuan, Z., additional, Wang, J., additional, Zeng, Z., additional, Chen, Y., additional, Yavuzgil, O., additional, Kozan, O., additional, Etemoglu, M., additional, Diker, E., additional, Belgi, A., additional, Ceyhan, C., additional, Cin, V., additional, Yilmaz, O., additional, Ata, N., additional, Altunkeser, B., additional, Agacdiken Agir, A., additional, Karadede, A., additional, Topsakal, R., additional, Gulati, R., additional, Madhavan, A., additional, Jain, S., additional, Oomman, A., additional, Janorkar, S., additional, Kumar, P., additional, Madhukar Naik, A., additional, Thacker, H., additional, Rajasekhar, V., additional, Reddy, R., additional, Keshavamurthy, C., additional, Jain, P., additional, Gowdappa, B., additional, Gadkari, M., additional, Abhyankar, A., additional, Ramesh Babu, B., additional, Vydianathan, P., additional, Sinha, S., additional, Garg, N., additional, Rao, S., additional, Gautam, P., additional, Chockalingam, K., additional, Kumbla, M., additional, Panwar, R., additional, Banker, D., additional, Kaste, M., additional, Jäkälä, P., additional, Roine, R., additional, Mihov, A., additional, Raev, D., additional, Yordanova, V., additional, Dimitrova, S., additional, Benov, H., additional, Tsanova, V., additional, Kyolean, M., additional, Marchev, S., additional, Stoikov, A., additional, Zdravkov, N., additional, Ramshev, K., additional, Krastev, A., additional, Stamenova, P., additional, Angelova, I., additional, Pencheva, G., additional, Grigorova, V., additional, Petrauskiene, B., additional, Skripkauskiene, I., additional, Raugaliene, R., additional, Norkiene, S., additional, Mazutavicius, R., additional, Kavoliuniene, A., additional, Aidietiene, S., additional, Aganauskiene, J., additional, Dailydkiene, A., additional, Marcinkeviciene, J., additional, Grigoniene, L., additional, Anusauskiene, J., additional, Kavaliauskiene, R., additional, Lizogub, V., additional, Rudenko, L., additional, Tseluyko, V., additional, Voronkov, L., additional, Sychov, O., additional, Svyshchenko, Y., additional, Sirenko, Y., additional, Serkova, V., additional, Seredyuk, N., additional, Pertseva, T., additional, Netyazhenko, V., additional, Lishnevska, V., additional, Kupchynska, O., additional, Koval, O., additional, Koshukova, G., additional, Karpenko, O., additional, Grishyna, O., additional, Faynyk, A., additional, Dzyak, G., additional, Dyadyk, O., additional, Yena, L., additional, Volkov, V., additional, Rudyk, I., additional, Kopytsya, M., additional, Kononenko, L., additional, Amosova, K., additional, Zhurba, S., additional, Kazimirko, V., additional, Iuzkiv, I., additional, Shershnyova, O., additional, Khomazyuk, T., additional, Batushkin, V., additional, Vykhovanyuk, I., additional, Popik, G., additional, Skrebkov, V., additional, Skurtov, A., additional, Mishchenko, T., additional, Lytvynenko, N., additional, Sokolova, L., additional, Vatutin, M., additional, Shved, M., additional, Rebrov, B., additional, Kadina, L., additional, Vajda, M., additional, Ursol, G., additional, Zheleznyy, V., additional, Vysochanska, T., additional, Gozhenko, A., additional, Fan, K., additional, Ho, D., additional, Tse, H., additional, Yu, C., additional, Wong, L., additional, Yeh, H., additional, Pai, P., additional, Hsieh, I., additional, Huang, C., additional, Hsieh, Y., additional, Yin, W., additional, Tsai, L., additional, Huang, T., additional, Chen, C., additional, Chiang, F., additional, Ueng, K., additional, Charng, M., additional, Marmor, A., additional, Katz, A., additional, Butnaru, A., additional, Lewis, B., additional, Eldar, M., additional, Rosenhack, S., additional, Elias, N., additional, Koifman, B., additional, Shochat, M., additional, Swissa, M., additional, Zimlichman, R., additional, Bental, T., additional, Weiss, A., additional, Ganam, R., additional, Elias, M., additional, Nseir, W., additional, Oliven, A., additional, Brenner, B., additional, and Dayan, M., additional

Published
2016
Full Text
View/download PDF

15. Early onset of hyperthension and serum electrolite changes as potential predictive factors of activity in advanced HCC treated with sorafeinb: Results from a retrospective analysis of HCC-AVR group

Author

Casadei Gardini, A., primary, Scarpi, E., additional, Marisi, G., additional, Foschi, G.F., additional, Donati, G., additional, Giampalma, E., additional, Faloppi, L., additional, Scartozzi, M., additional, Silvestris, N., additional, Bisulli, M., additional, Corbelli, J., additional, Gardini, A., additional, La Barba, G., additional, Veneroni, L., additional, Tamberi, S., additional, Cascinu, S., additional, and Frassineti, G.L., additional

Published
2016
Full Text
View/download PDF

16. ENOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS Study

Author

Casadei Gardini, A., primary, Marisi, G., additional, Faloppi, L., additional, Scarpi, E., additional, Foschi, F.G., additional, Iavarone, M., additional, Lauletta, G., additional, Corbelli, J., additional, Tenti, E., additional, Facchetti, F., additional, della Corte, C., additional, Tamberi, S., additional, Cascinu, S., additional, Scartozzi, M., additional, Amadori, D., additional, Nanni, O., additional, Ulivi, P., additional, and Frassineti, G.L., additional

Published
2016
Full Text
View/download PDF

17. Multicentric Prospective Study of Validation of Angiogenesis Polymorphisms in HCC Patients Treated with Sorafenib. Innovate Study

Author

Gardini, A.C., primary, Faloppi, L., additional, Daniele, B., additional, Foschi, G.F., additional, Cascinu, S., additional, Marisi, G., additional, Masi, G., additional, Chessa, L., additional, Negri, F., additional, Scarpi, E., additional, Santini, D., additional, Corbelli, J., additional, Silvestris, N., additional, Tamburini, E., additional, Zagonel, V., additional, and Scartozzi, M., additional

Published
2016
Full Text
View/download PDF

19. eNOS polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib. Final results of ePHAS study

Author

Casadei Gardini, A., primary, Marisi, G., additional, Scartozzi, M., additional, Faloppi, L., additional, Foschi, F., additional, Corbelli, J., additional, Scarpi, E., additional, Iavarone, M., additional, Lauletta, G., additional, Ulivi, P., additional, Tamberi, S., additional, Nanni, O., additional, Cascinu, S., additional, Tenti, E., additional, and Frassineti, G.L., additional

Published
2015
Full Text
View/download PDF

21. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer

Author

Fornaro, L, primary, Cereda, S, additional, Aprile, G, additional, Di Girolamo, S, additional, Santini, D, additional, Silvestris, N, additional, Lonardi, S, additional, Leone, F, additional, Milella, M, additional, Vivaldi, C, additional, Belli, C, additional, Bergamo, F, additional, Lutrino, S E, additional, Filippi, R, additional, Russano, M, additional, Vaccaro, V, additional, Brunetti, A E, additional, Rotella, V, additional, Falcone, A, additional, Barbera, M A, additional, Corbelli, J, additional, Fasola, G, additional, Aglietta, M, additional, Zagonel, V, additional, Reni, M, additional, Vasile, E, additional, and Brandi, G, additional

Published
2014
Full Text
View/download PDF

23. Second-line chemotherapy in patients with biliary tract cancer.

Author

Brandi, G., primary, Di Girolamo, S., additional, de Rosa, F., additional, Corbelli, J., additional, Agostini, V., additional, Garajova, I., additional, Longobardi, C., additional, Paragona, M., additional, Ercolani, G., additional, Pinna, A. D., additional, and Biasco, G., additional

Published
2011
Full Text
View/download PDF

28. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia.

Author

Kerzner B, Corbelli J, Sharp S, Lipka LJ, Melani L, LeBeaut A, Suresh R, Mukhopadhyay P, Veltri EP, Ezetimibe Study Group, Kerzner, Boris, Corbelli, John, Sharp, Stephan, Lipka, Leslie J, Melani, Lorenzo, LeBeaut, Alexandre, Suresh, Ramachandran, Mukhopadhyay, Pabak, and Veltri, Enrico P

Abstract

This multicenter, randomized, double-blind, placebo-controlled clinical study assessed the efficacy and safety of ezetimibe administered with lovastatin in primary hypercholesterolemia. After dietary stabilization, a 2- to 12-week washout period, and a 4-week single-blind placebo lead-in period, 548 patients with low-density lipoprotein (LDL) cholesterol > or =145 mg/dl (3.75 mmol/L) and < or =250 mg/dl (6.47 mmol/L) and triglycerides < or =350 mg/dl (3.99 mmol/L) were randomized to one of the following, administered daily for 12 weeks: ezetimibe 10 mg; lovastatin 10, 20, or 40 mg; ezetimibe 10 mg plus lovastatin 10, 20, or 40 mg; or placebo. The primary efficacy variable was percentage decrease in direct LDL cholesterol from baseline to end point for pooled ezetimibe plus lovastatin versus pooled lovastatin alone. Ezetimibe plus lovastatin significantly improved concentrations of LDL cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides compared with lovastatin alone (p <0.01). The coadministration of ezetimibe provided an incremental 14% LDL cholesterol decrease, a 5% HDL cholesterol increase, and a 10% decrease in triglycerides compared with pooled lovastatin alone. Ezetimibe plus lovastatin provided mean LDL cholesterol decreases of 33% to 45%, median triglyceride decreases of 19% to 27%, and mean HDL cholesterol increases of 8% to 9%, depending on the statin dose. The coadministration of ezetimibe 10 mg plus the starting dose of lovastatin (10 mg) provided comparable efficacy to high-dose lovastatin (40 mg) across the lipid profile (LDL cholesterol, HDL cholesterol, and triglycerides). Ezetimibe plus lovastatin was well tolerated, with a safety profile similar to both lovastatin alone and placebo. The coadministration of ezetimibe and lovastatin may offer a new treatment option in lipid management of patients with hypercholesterolemia. [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

29. A new method for evaluating the effect of antiarrhythmic drugs on atrioventricular nodal conduction.

Author

Lévy, S, Hilaire, J, Albin, H, Corbelli, J L, Burtey, J P, Bricaud, H, and Gérard, R

Abstract

Electrophysiological variables were studied in 19 patients before and after one of three commonly used antiarrhythmic agents. The pacing rate at which alternating Wenckebach periods appeared in eight patients was significantly reduced by intravenous digoxin (0.01 mg/kg body weight). The atrioventricular nodal conduction time (A-H interval) and Wenckebach point were not significantly altered by digoxin. Intravenous propranolol (0.1 mg/kg body weight) in four patients did not affect the A-H interval, but it reduced the pacing rates at which the Wenckebach point and alternating Wenckebach periods occurred. Intravenous disopyramide (2 mg/kg body weight) significantly increased the pacing rate required to produce alternating Wenckebach periods but did not significantly alter the other indicators of atrioventricular conduction in seven patients. It is concluded that the pacing rate required to produce alternating Wenckebach periodicity may be a useful and sensitive variable in the evaluation of the effect of antiarrhythmic agents on atrioventricular nodal conduction. [ABSTRACT FROM PUBLISHER]

Published
1986
Full Text
View/download PDF

30. Occupational exposure to asbestos: a putative unknown risk factor for intrahepatic cholangiocarcinoma

Author

Brandi, Giovanni, Di Girolamo, S., Farioli, A., Rosa, F., Curti, Stefania, Corbelli, J., Longobardi, C., Agostini, V., Garajova, Ingrid, Paragona, M., Violante, Fs, Biasco, Guido, Stefano Mattioli, Brandi G, Di Girolamo S, Farioli A, de Rosa F, Curti S, Corbelli J, Longobardi C, Agostini V, Garajová I, Paragona M, Violante FS, Biasco G, and Mattioli S.

Subjects
Economica, Socio-culturale

31. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial†

Author

Tardif, Jean-Claude, Ballantyne, Christie M., Barter, Philip, Dasseux, Jean-Louis, Fayad, Zahi A., Guertin, Marie-Claude, Kastelein, John J. P., Keyserling, Constance, Klepp, Heather, Koenig, Wolfgang, L'Allier, Philippe L., Lespérance, Jacques, Lüscher, Thomas F., Paolini, John F., Tawakol, Ahmed, Waters, David D., Pfeffer, M., Brown, V., Rouleau, J., Watkins, P., Wei, L.J., Gosselin, G., Chayer, C., Lanthier, S., Pelletier, G.B., Racine, N., Agarwal, H., Brilakis, E., Cannon, L., Carrié, D., Corbelli, J., Coste, P., de Winter, R., Diaz, A., Eisenberg, S., Ennis, B., Fajadet, J., Fam, N., Fortuin, D., Gessler, C., Grines, C., Guerra, D., Gum, H., Haldis, T., Heestermans, T., Herrman, J.P., Huynh, T., Kedhi, E., Koren, M., Kouz, S., Krolick, M., Kumkumian, G., Lavi, S., Li, R.J., Masud, ARZ, McAlhany, C., McGrew, F.A., O'Shaughnessy, C., Oude Ophuis, A.J.M., Parr, K., Penny, W., Pesant, Y., Post, H., Robinson, S., Rodes-Cabau, J., Roy, A., Schulman, S., Spence, F., Stouffer, G., Stys, T., Sussex, B., Tahirkheli, N., Tardif, J-C, Grégoire, J., ten Berg, J., van Boven, A.J., von Birgelen, C., Weinstein, D., Tardif, Jean-Claude, Ballantyne, Christie M., Barter, Philip, Dasseux, Jean-Louis, Fayad, Zahi A., Guertin, Marie-Claude, Kastelein, John J. P., Keyserling, Constance, Klepp, Heather, Koenig, Wolfgang, L'Allier, Philippe L., Lespérance, Jacques, Lüscher, Thomas F., Paolini, John F., Tawakol, Ahmed, Waters, David D., Pfeffer, M., Brown, V., Rouleau, J., Watkins, P., Wei, L.J., Gosselin, G., Chayer, C., Lanthier, S., Pelletier, G.B., Racine, N., Agarwal, H., Brilakis, E., Cannon, L., Carrié, D., Corbelli, J., Coste, P., de Winter, R., Diaz, A., Eisenberg, S., Ennis, B., Fajadet, J., Fam, N., Fortuin, D., Gessler, C., Grines, C., Guerra, D., Gum, H., Haldis, T., Heestermans, T., Herrman, J.P., Huynh, T., Kedhi, E., Koren, M., Kouz, S., Krolick, M., Kumkumian, G., Lavi, S., Li, R.J., Masud, ARZ, McAlhany, C., McGrew, F.A., O'Shaughnessy, C., Oude Ophuis, A.J.M., Parr, K., Penny, W., Pesant, Y., Post, H., Robinson, S., Rodes-Cabau, J., Roy, A., Schulman, S., Spence, F., Stouffer, G., Stys, T., Sussex, B., Tahirkheli, N., Tardif, J-C, Grégoire, J., ten Berg, J., van Boven, A.J., von Birgelen, C., and Weinstein, D.

Abstract

Aim High-density lipoproteins (HDLs) have several potentially protective vascular effects. Most clinical studies of therapies targeting HDL have failed to show benefits vs. placebo. Objective To investigate the effects of an HDL-mimetic agent on atherosclerosis by intravascular ultrasonography (IVUS) and quantitative coronary angiography (QCA). Design and setting A prospective, double-blinded, randomized trial was conducted at 51 centres in the USA, the Netherlands, Canada, and France. Intravascular ultrasonography and QCA were performed to assess coronary atherosclerosis at baseline and 3 (2-5) weeks after the last study infusion. Patients Five hundred and seven patients were randomized; 417 and 461 had paired IVUS and QCA measurements, respectively. Intervention Patients were randomized to receive 6 weekly infusions of placebo, 3 mg/kg, 6 mg/kg, or 12 mg/kg CER-001. Main outcome measures The primary efficacy parameter was the nominal change in the total atheroma volume. Nominal changes in per cent atheroma volume on IVUS and coronary scores on QCA were also pre-specified endpoints. Results The nominal change in the total atheroma volume (adjusted means) was −2.71, −3.13, −1.50, and −3.05 mm3 with placebo, CER-001 3 mg/kg, 6 mg/kg, and 12 mg/kg, respectively (primary analysis of 12 mg/kg vs. placebo: P = 0.81). There was also no difference among groups for the nominal change in per cent atheroma volume (0.02, −0.02, 0.01, and 0.19%; nominal P = 0.53 for 12 mg/kg vs. placebo). Change in the coronary artery score was −0.022, −0.036, −0.022, and −0.015 mm (nominal P = 0.25, 0.99, 0.55), and change in the cumulative coronary stenosis score was −0.51, 2.65, 0.71, and −0.77% (compared with placebo, nominal P = 0.85 for 12 mg/kg and nominal P = 0.01 for 3 mg/kg). The number of patients with major cardiovascular events was 10 (8.3%), 16 (13.3%), 17 (13.7%), and 12 (9.8%) in the four groups. Conclusion CER-001 infusions did not reduce coronary atherosclerosis on IVUS and QC

35. Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol

Author

Giorgio de Stefano, Arianna Lanzi, Oronzo Brunetti, Daniele Bruno, Francesca Negri, Luca Faloppi, Umberto Vespasiani Gentilucci, Flavia Pagan, Giovanni Luca Frassineti, Marianna Silletta, Mario Scartozzi, Vittorina Zagonel, Daniele Santini, Andrea Casadei Gardini, Luchino Chessa, Vincenzo Dadduzio, Giorgia Marisi, Francesco Giuseppe Foschi, Stefano Cascinu, Emiliano Tamburini, Nicola Silvestris, Gianluca Masi, Lorenzo Calvetti, Giorgio Ercolani, Caterina Vivaldi, Chiara Caparello, Alessandro Leonetti, Giuseppe Aprile, N. Farella, Emanuela Scarpi, Davide Tassinari, Jody Corbelli, Gardini, A. C., Faloppi, L., Aprile, G., Brunetti, O., Caparello, C., Corbelli, J., Chessa, L., Bruno, D., Ercolani, G., Leonetti, A., De Stefano, G., Farella, N., Foschi, F. G., Lanzi, A., Dadduzio, V., Marisi, G., Masi, G., Negri, F. V., Pagan, F., Santini, D., Scarpi, E., Silletta, M., Silvestris, N., Tamburini, E., Tassinari, D., Vivaldi, C., Gentilucci, U. V., Zagonel, V., Calvetti, L., Cascinu, S., Frassineti, G. L., and Scartozzi, M.

Subjects
Male, Vascular Endothelial Growth Factor A, 0301 basic medicine, Oncology, Cancer Research, Hepatocellular carcinoma, Angiogenesis, VEGF receptors, Trial, 0302 clinical medicine, Prospective Studies, Prospective cohort study, Neovascularization, Pathologic, biology, ENOS, Angiopoietin 2, Liver Neoplasms, General Medicine, Sorafenib, VEGF, 030220 oncology & carcinogenesis, eNOS, Female, Hypoxia-Inducible Factor 1, Biomarkers, medicine.drug, medicine.medical_specialty, Disease free survival, Carcinoma, Hepatocellular, Standard of care, Adolescent, Nitric Oxide Synthase Type III, Antineoplastic Agents, Polymorphism, Single Nucleotide, Disease-Free Survival, Angiopoietin-2, 03 medical and health sciences, Internal medicine, medicine, Humans, neoplasms, business.industry, medicine.disease, digestive system diseases, Receptors, Vascular Endothelial Growth Factor, 030104 developmental biology, biology.protein, business
Abstract

Introduction: Although sorafenib is the upfront standard of care for advanced hepatocellular carcinoma (HCC), molecular predictors of efficacy have not been identified yet. In the ALICE-1 study, rs2010963 of VEGF-A and VEGF-C proved to be independent predictive factors for progression-free survival (PFS) and overall survival (OS) in multivariate analysis. The ALICE-1 study results were confirmed in the ALICE-2 study, in which VEGF and VEGFR SNPs were analyzed. In the ePHAS study we analyzed the SNPs of eNOS. In univariate analysis, patients homozygous for an eNOS haplotype (HT1: T-4b at eNOS-786/eNOS VNTR) had significantly shorter median PFS and OS than those with other haplotypes. These data were confirmed in the validation set. Methods: This nonpharmacological, interventional, prospective multicenter study aims to determine whether eNOS, HIF-1, VEGF, Ang2 and VEGFR polymorphisms play a role in predicting the objective response rate, PFS, and OS of advanced HCC patients treated with sorafenib. The study will involve 160 advanced HCC patients with Child-Pugh class A disease. The primary aim is to validate the prognostic or predictive roles of eNOS, Ang2, HIF-1, VEGF and VEGFR polymorphisms in relation to the clinical outcome (PFS) of HCC patients treated with sorafenib. Conclusions: Overall, our data may suggest that polymorphism analysis of the VEGF, VEGFR-2, HIF and eNOS genes can identify HCC patients who are more likely to benefit from sorafenib.

Published
2018

36. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer

Author

Massimo Aglietta, Roberto Filippi, Enrico Vasile, Virginia Rotella, Caterina Vivaldi, Sara Lonardi, Giovanni Brandi, Gianpiero Fasola, Stefania Eufemia Lutrino, M. Milella, Marco Russano, Jody Corbelli, Lorenzo Fornaro, N. Silvestris, G. Aprile, Francesco Leone, Alfredo Falcone, Michele Reni, Daniele Santini, Carmen Belli, Maria Aurelia Barbera, Vittorina Zagonel, Stefano Cereda, Vanja Vaccaro, Anna Elisabetta Brunetti, Francesca Bergamo, S. Di Girolamo, Fornaro L, Cereda S, Aprile G, Di Girolamo S, Santini D, Silvestris N, Lonardi S, Leone F, Milella M, Vivaldi C, Belli C, Bergamo F, Lutrino SE, Filippi R, Russano M, Vaccaro V, Brunetti AE, Rotella V, Falcone A, Barbera MA, Corbelli J, Fasola G, Aglietta M, Zagonel V, Reni M, Vasile E, and Brandi G

Subjects
Oncology, second-line, Adult, Male, Cancer Research, medicine.medical_specialty, Pathology, Multivariate analysis, Colorectal cancer, chemotherapy, Disease-Free Survival, Prostate cancer, Breast cancer, Internal medicine, 80 and over, Medicine, Humans, Lung cancer, advanced biliary tract cancer, prognostic factors, Aged, Retrospective Studies, Cervical cancer, Aged, 80 and over, Biliary tract neoplasm, business.industry, Middle Aged, medicine.disease, Prognosis, Neoplasm Recurrence, Biliary Tract Neoplasms, Local, Italy, Multivariate Analysis, Clinical Study, Disease Progression, Female, Neoplasm Recurrence, Local, business, Liver cancer
Abstract

Background: The role of second-line chemotherapy (CT) is not established in advanced biliary tract cancer (aBTC). We investigated the outcome of aBTC patients treated with second-line CT and devised a prognostic model. Methods: Baseline clinical and laboratory data of 300 consecutive aBTC patients were collected and association with overall survival (OS) was investigated by multivariable Cox models. Results: The following parameters resulted independently associated with longer OS: Eastern Cooperative Oncology Group performance status of 0 (P

Published
2014

37. Prognostic model for patients with advanced biliary tract cancer (ABTC) receiving second-line chemotherapy (CT)

Author

Fornaro L, Cereda S, Bergamo F, Lutrino SE, Leone F, Vaccaro V, Silvestris N, Vasile E, Milella M, Aprile G, Vivaldi C, Barbera A, Filippi R, Caparello C, Mioranza E, Ferrari L, Baldini E, Reni M, BRANDI, GIOVANNI, SANTINI, DONATELLA, CORBELLI, JODY, Fornaro L, Cereda S, Bergamo F, Lutrino SE, Leone F, Santini D, Vaccaro V, Silvestris N, Corbelli J, Vasile E, Milella M, Aprile G, Vivaldi C, Barbera A, Filippi R, Caparello C, Mioranza E, Ferrari L, Baldini E, Reni M, and Brandi G

Subjects
biliary tract cancer
Published
2013

38. Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) predicts better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients

Author

BRANDI, GIOVANNI, TAVOLARI, SIMONA, FREGA, GIORGIO, CORBELLI, JODY, PANTALEO, MARIA ABBONDANZA, BIASCO, GUIDO, Vasuri F, Farioli A, Deserti M, Barbera MA, Di Girolamo S, Brandi G, Tavolari S, Vasuri F, Farioli A, Deserti M, Frega G, Corbelli J, Barbera MA, Pantaleo MA, Di Girolamo S, and Biasco G.

Subjects
hENT-1
Published
2013

39. A multicenter survey on second-line chemotherapy for advanced biliary tract cancer

Author

Vasile E, Cereda S, Lutrino SE, Lonardi S, Leone F, Russano M, Vaccaro V, Del Curatolo S, Fornaro L, Caponi S, Rotella V, Vivaldi C, Filippi R, Cardellino GG, Daniel F, Reni M, BRANDI, GIOVANNI, CORBELLI, JODY, SANTINI, DONATELLA, DI GIROLAMO, STEFANIA, Vasile E, Cereda S, Lutrino SE, Lonardi S, Leone F, Russano M, Vaccaro V, Del Curatolo S, Corbelli J, Fornaro L, Caponi S, Santini D, Rotella V, Vivaldi C, Di Girolamo S, Filippi R, Cardellino GG, Daniel F, Reni M, and Brandi G

Subjects
biliary tract cancer
Published
2013

40. Second surgery or chemotherapy for relapse after radical resection of colorectal cancer metastases

Author

Ingrid Garajová, Gian Luca Grazi, Jody Corbelli, Giorgio Ercolani, Stefano La Rovere, Antonio Daniele Pinna, Stefania Di Girolamo, Ciro Longobardi, Giovanni Brandi, Francesco De Rosa, Guido Biasco, Valentina Agostini, Brandi G, Corbelli J, de Rosa F, Di Girolamo S, Longobardi C, Agostini V, Garajová I, La Rovere S, Ercolani G, Grazi GL, Pinna AD, and Biasco G

Subjects
Diagnostic Imaging, Male, Reoperation, medicine.medical_specialty, Lung Neoplasms, Colorectal cancer, medicine.medical_treatment, ADJUVANT THERAPY, Colorectal cancer metastases, Metastasectomy,Integrated treatment, Neoadjuvant therapy, Adjuvant therapy, Colorectal cancer metastases, Statistics, Nonparametric, NO, Colorectal cancer metastase, Biomarkers, Tumor, medicine, Adjuvant therapy, Humans, Neoadjuvant therapy, Neoplasm Staging, Proportional Hazards Models, Retrospective Studies, Chemotherapy, business.industry, General surgery, Liver Neoplasms, Metastasectomy, Middle Aged, Vascular surgery, medicine.disease, Integrated treatment, Combined Modality Therapy, Surgery, Survival Rate, Treatment Outcome, Chemotherapy, Adjuvant, Cardiothoracic surgery, Disease Progression, Female, Neoplasm Recurrence, Local, Colorectal Neoplasms, business, Abdominal surgery
Abstract

Purpose Limited data suggest that second resections for colorectal cancer metastases may improve survival, but no study has compared surgery with chemotherapy in this setting. Therefore, we retrospectively compared the clinical outcome of potentially resectable patients who received a second metastasectomy with those who did not in our single-centre experience. Methods We retrospectively reviewed the clinical records of all patients treated for metastatic colorectal cancer in our centre over a period of 12 years. We selected patients who relapsed after radical resection of metastases from colorectal cancer and were deemed resectable again by our multidisciplinary team. We then compared the clinical outcome of those who received a second operation with those who refused surgery and also evaluated the role of prognostic factors. Results We identified 60 patients fulfilling the inclusion criteria. Twenty-nine underwent a second resection and 31 refused surgery. Median overall survival rates were 58.7 and 24.0 months, median times to progression were 14.4 and 6.6 months. Patients who received surgery plus perioperatory chemotherapy (18/29) had a significantly better outcome; 4/29 achieved long-term disease-free survival. Conclusions Our study suggests that in highly selected metastatic colorectal cancer patients, a multimodal treatment plan, including a second resection, can achieve longer survival with respect to medical therapy.

Published
2012

41. Feasibility of triplets (5-FU, oxaliplatin and irinotecan based) in front and subsequent lines of metastatic colorectal cancer patients

Author

LONGOBARDI, CIRO, BRANDI, GIOVANNI, CORBELLI, JODY, DE ROSA, FRANCESCO, AGOSTINI, VALENTINA, BIASCO, GUIDO, Bruera G, Di Girolamo S, Casolino R, GARAJOVA, INGRID, Ficorella C., Longobardi C, Brandi G, Bruera G, Corbelli J, de Rosa F, Di Girolamo S, Casolino R, Agostini V, Garajovà I, Biasco G, and Ficorella C.

Subjects
5-FU, irinotecan, oxaliplatinum
Published
2011

42. Metronomic capecitabine as second-line treatment after sorafenib for hepatocelllular carcinoma

Author

DE ROSA, FRANCESCO, CORBELLI, JODY, LONGOBARDI, CIRO, AGOSTINI, VALENTINA, ANDREONE, PIETRO, PISCAGLIA, FABIO, GOLFIERI, RITA, BOLONDI, LUIGI, PINNA, ANTONIO DANIELE, BIASCO, GUIDO, BRANDI, GIOVANNI, Di Girolamo S, Serra C, TREVISANI, FRANCO, de Rosa F, Di Girolamo S, Corbelli J, Longobardi C, Agostini V, Andreone P, Serra C, Piscaglia F, Trevisani F, Golfieri R, Bolondi L, Pinna AD, Biasco G, and Brandi G.

Subjects
HCC
Published
2011

43. Asbestos: a putative risk factor for intrahepatic cholangiocarcinoma

Author

Stefano Mattioli, Di Girolamo, S., Farioli, A., Rosa, Francesco, Curti, Stefania, Corbelli, Jody, Longobardi, Ciro, Agostini, Valentina, Garajova, Ingrid, Paragona, Marco, Violante, Fs, Biasco, Guido, Brandi, Giovanni, Mattioli S, Di Girolamo S, Farioli A, de Rosa F, Curti S, Corbelli J, Longobardi C, Agostini V, Garajovà I, Paragona M, Violante FS, Biasco G, and Brandi G

Subjects
Economica, Socio-culturale, Ambientale, cholangiocarcinoma
Published
2011

44. Second-line chemotherapy in biliary tract cancer patients

Author

CORBELLI, JODY, DE ROSA, FRANCESCO, AGOSTINI, VALENTINA, LONGOBARDI, CIRO, PARAGONA, MARCO, ERCOLANI, GIORGIO, PINNA, ANTONIO DANIELE, BIASCO, GUIDO, BRANDI, GIOVANNI, Di Girolamo S, GARAJOVA, INGRID, Corbelli J, Di Girolamo S, de Rosa F, Agostini V, Garajovà I, Longobardi C, Paragona M, Ercolani G, Pinna AD, Biasco G, and Brandi G.

Subjects
biliary tract cancer
Published
2011

45. Venous thromboembolism and port-related thrombosis in metastatic colorectal cancer patients: a monocenter experience

Author

Marco Paragona, Guido Biasco, Antonio Maria Morselli-Labate, Marina Macchini, Monica Di Battista, Giovanni Brandi, Roberto Di Cicilia, Jody Corbelli, Elisabetta Nobili, Paolo Prandoni, Nobili E, Di Cicilia R, Di Battista M, Morselli-Labate AM, Paragona M, Corbelli J, Macchini M, Prandoni P, Biasco G, and Brandi G.

Subjects
Oncology, Adult, Male, medicine.medical_specialty, Antimetabolites, Antineoplastic, Catheterization, Central Venous, Colorectal cancer, medicine.medical_treatment, Risk Factors, Physiology (medical), Internal medicine, Upper Extremity Deep Vein Thrombosis, Antineoplastic Combined Chemotherapy Protocols, Outpatients, medicine, Humans, cardiovascular diseases, Risk factor, Aged, Retrospective Studies, Aged, 80 and over, Chemotherapy, business.industry, Incidence (epidemiology), Cancer, Retrospective cohort study, Hematology, Venous Thromboembolism, Middle Aged, medicine.disease, equipment and supplies, Thrombosis, Female, Fluorouracil, Morbidity, business, Colorectal Neoplasms, Central venous catheter
Abstract

Venous thromboembolism (VTE) may occur during the natural history of neoplastic disease and is a common cause of mortality and morbidity in cancer patients. Major risk factors for VTE in cancer patients include surgery, immobilization, hospitalization, and the administration of granulopoietic and/or erythropoietic (stimulatory) agents. Chemotherapy is a supplementary independent risk factor for VTE and the use of central venous catheters (CVC) in clinical practice has increased the risk of thromboembolic events. We conducted a retrospective study to evaluate CVC-related thrombosis and the VTE rate in 145 consecutive metastatic colorectal cancer patients. We observed only 2 cases of symptomatic CVC- related thrombotic events (1.38%) and 10 cases of thromboembolic events (6.9%) in our series. Only surgery for metastases was found to be significantly related to the development of VTE, with an incidence of 16.1% vs. 4.4 in patients who did not undergo surgery (p = 0.037). In addition, a history of VTE seems to be a supplementary risk factor for CVC-related thrombosis (p = 0.055).

Published
2010

46. The Effect of Geographic Cohorting of Inpatient Teaching Services on Patient Outcomes and Resident Experience.

Author

Klein AJ, Veet C, Lu A, Kennedy AJ, Agonafer E, Grau T, Rothenberger SD, and Corbelli J

Subjects
Aged, Female, Humans, Length of Stay, Male, Medicare, Middle Aged, Patient Discharge, Patient Readmission, Retrospective Studies, United States, Inpatients, Patient Satisfaction
Abstract

Background: Geographic cohorting is a hospital admission structure in which every patient on a given physician team is admitted to a dedicated hospital unit. Little is known about the long-term impact of this admission structure on patient outcomes and resident satisfaction., Objective: To evaluate the effect of geographic cohorting on patient outcomes and resident satisfaction among inpatient internal medicine teaching services within an academic hospital., Design and Intervention: We conducted an interrupted time series analysis examining patient outcomes before and after the transition to geographic cohorting of our 3 inpatient teaching services within a 520-bed academic hospital in November 2017. The study observation period spanned from January 2017 to October 2018, allowing for a 2-month run-in period (November-December 2017)., Participants: We included patients discharged from the inpatient teaching teams during the study period. We excluded patients admitted to the ICU and observation admissions., Main Measures: Primary outcome was 6-month mortality adjusted for patient age, sex, race, insurance status, and Charlson Comorbidity Index (CCI) analyzed using a linear mixed effects model. Secondary outcomes included hospital length of stay (LOS), 7-day and 30-day readmission rate, Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores, and resident evaluations of the rotation., Key Results: During the observation period, 1720 patients (mean age 64, 53% female, 56% white, 62% Medicare-insured, mean CCI 1.57) were eligible for inclusion in the final adjusted model. We did not detect a significant change in 6-month mortality, LOS, and 7-day or 30-day readmission rates. HCAHPS scores remained unchanged (77 to 80% top box, P = 0.19), while resident evaluations of the rotation significantly improved (mean overall score 3.7 to 4.0, P = 0.03)., Conclusions: Geographic cohorting was associated with increased resident satisfaction while achieving comparable patient outcomes to those of traditional hospital admitting models., (© 2022. The Author(s) under exclusive licence to Society of General Internal Medicine.)

Published
2022
Full Text
View/download PDF

47. Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer.

Author

Grassi E, Corbelli J, Papiani G, Barbera MA, Gazzaneo F, and Tamberi S

Abstract

Around 8-12% of patients with advanced colon rectal cancer (CRC) present with BRAF alterations, in particular V600E mutation, which is associated with right-side, poorly differentiated and mucinous type tumors. The presence of BRAF mutation (BRAF-mt) has been identified as a hallmark of poor prognosis and treatment optimization in this patient subgroup is an important goal. Currently, the standard of care is an aggressive strategy involving triplet chemotherapy and anti-VEGF agents, but new therapeutic approaches are emerging. Very promising results have been obtained with targeted therapy combinations, such as anti-BRAF agents plus anti-EGFR agents. Furthermore, around 60% of BRAF-mt patients show a strong association with high microsatellite instability (MSI-H) and immune checkpoint inhibitors could represent the new standard of care for this subgroup. The focus of this review is to summarize current strategies for BRAF-mt CRC treatment and highlight new therapeutic options., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Grassi, Corbelli, Papiani, Barbera, Gazzaneo and Tamberi.)

Published
2021
Full Text
View/download PDF

48. A Resident-Authored, Case-Based Electrocardiogram Email Curriculum for Internal Medicine Residents.

Author

Klein AJ, Berlacher M, Doran JA, Corbelli J, Rothenberger SD, and Berlacher K

Subjects
Clinical Competence, Curriculum, Educational Measurement, Electrocardiography, Humans, Electronic Mail, Internship and Residency
Abstract

Introduction: The interpretation of electrocardiograms (ECGs) is a critical competency for internal medicine trainees, yet time and resources to foster proficiency are limited., Methods: This resident-authored ECG email curriculum for first-year residents involved 129 first-year internal medicine residents at three major academic university hospitals. Residents either received the resident-authored ECG email curriculum (intervention group) or continued standard training (control group). The curriculum involved 10 multiple-choice ECG cases emailed biweekly over the 6-month study period. All participants were asked to complete a pre- and postintervention test to assess ECG interpretation competency and attitudes. The primary outcome was improvement in ECG test performance., Results: Among the 129 first-year residents participating, 21 of the 65 (32%) randomized to the intervention group and 13 of the 64 (20%) randomized to the control group completed both the pre- and posttests for analysis. While all participants' ECG test scores improved over the study period ( p < .001), improvement did not differ between groups ( p = .860). We found that the effect of the intervention on ECG test performance varied significantly by the number of cardiology rotations an intern experienced ( p = .031), benefiting naïve learners the most. All intervention group participants who completed the posttest reported they would recommend it to a colleague., Discussion: While it did not improve resident performance on an ECG posttest, this resident-authored ECG email curriculum offers a scalable way to provide trainees additional practice with ECG interpretation, with particular benefit to trainees who have not yet rotated on cardiology., (© 2020 Klein et al.)

Published
2020
Full Text
View/download PDF

49. The impact of residents sitting at the bedside on patient satisfaction during team rounds.

Author

Donovan AK, Spagnoletti C, Rothenberger S, and Corbelli J

Subjects
Academic Medical Centers, Attitude of Health Personnel, Humans, Sitting Position, Teaching, Internal Medicine education, Internal Medicine methods, Internship and Residency methods, Patient Satisfaction, Teaching Rounds trends
Abstract

Objectives: Patient satisfaction ratings are a priority for academic medical centers. Sitting during patient encounters has been recommended as a "best practice." 1 A prior study showed that hospitalists had higher-rated communication skills when sitting compared to standing at the bedside during rounds. 2 It is unclear whether the same is true of resident-led team rounds., Methods: We performed a cluster-randomized crossover trial assigning 18 internal medicine residents to sit or stand at the bedside during rounds., Results: A total of 347 patients were surveyed to assess physician communication skills. Standing residents received higher ratings than sitting residents on 2 of 5 survey items and rounding duration did not differ. These results differ from prior work that suggests sitting is superior to standing 2-6 ., Conclusion: We suspect that one rounding member sitting, while all others stand, is not enough to impact patients' perceptions. These results suggest that initiatives to optimize patient satisfaction on resident-staffed units should be focused elsewhere., Practice Implications: Patients do not have better impressions of physician communication skills when one team member is sitting and the rest are standing., Competing Interests: Declaration of Competing Interest The authors have no conflicts of interest to disclose., (Copyright © 2019 Elsevier B.V. All rights reserved.)

Published
2020
Full Text
View/download PDF

50. Comparing Specialty and Primary Palliative Care Interventions: Analysis of a Systematic Review.

Author

Ernecoff NC, Check D, Bannon M, Hanson LC, Dionne-Odom JN, Corbelli J, Klein-Fedyshin M, Schenker Y, Zimmermann C, Arnold RM, and Kavalieratos D

Subjects
Health Personnel, Humans, Quality of Life, Specialization, Hospice and Palliative Care Nursing, Palliative Care
Abstract

Background: Investigators have tested interventions delivered by specialty palliative care (SPC) clinicians, or by clinicians without palliative care specialization (primary palliative care, PPC). Objective: To compare the characteristics and outcomes of randomized clinical trials (RCTs) of SPC and PPC interventions. Design: Systematic review secondary analysis. Setting/Subjects: RCTs of palliative care interventions. Measurements: Interventions were classified SPC if delivered by palliative care board-certified or subspecialty trained clinicians, or those with extensive clinical experience; all others were PPC. We abstracted data for each intervention: delivery setting, delivery clinicians, outcomes measured, trial results, and Cochrane's Risk of Bias. We conducted narrative synthesis for quality of life, symptom burden, and survival. Results: Of 43 RCTs, 27 tested SPC and 16 tested PPC interventions. SPC interventions were more comprehensive (4.2 elements of palliative care vs. 3.1 in PPC, p  = 0.02). SPC interventions were delivered in inpatient (44%) or outpatient settings (52%) by specialty physicians (44%) and nurses (44%); PPC interventions were delivered in inpatient (38%) and home settings (38%) by nurses (75%). PPC trials were more often of high risk of bias than SPC trials. Improvements were demonstrated on quality of life by SPC and PPC trials and on physical symptoms by SPC trials. Conclusions: Compared to PPC, SPC interventions were more comprehensive, were more often delivered in clinical settings, and demonstrated stronger evidence for improving physical symptoms. In the face of SPC workforce limitations, PPC interventions should be tested in more trials with low risk of bias, and may effectively meet some palliative care needs.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results